{"id":"eribulin","rwe":[{"pmid":"41894563","year":"2026","title":"CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.","finding":"","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","studyType":"Clinical Study"},{"pmid":"41892363","year":"2026","title":"Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay.","finding":"","journal":"Epigenomes","studyType":"Clinical Study"},{"pmid":"41879493","year":"2026","title":"Marine-Derived Anticancer Compounds and their Clinical Status.","finding":"","journal":"Anti-cancer agents in medicinal chemistry","studyType":"Clinical Study"},{"pmid":"41855129","year":"2026","title":"Across borders and histologies: Rethinking endpoints for vascular sarcoma trials.","finding":"","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","studyType":"Clinical Study"},{"pmid":"41854792","year":"2026","title":"Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.","finding":"","journal":"Breast cancer research and treatment","studyType":"Clinical Study"}],"_fda":{"id":"5b72f089-3089-d1f4-1138-d21ea2958492","set_id":"1038e984-3bf7-5bbf-f1ec-ce15ae330efc","openfda":{"upc":["0343598125114"],"unii":["AV9U0660CW"],"route":["INTRAVENOUS"],"rxcui":["1045456"],"spl_id":["5b72f089-3089-d1f4-1138-d21ea2958492"],"brand_name":["Eribulin Mesylate"],"spl_set_id":["1038e984-3bf7-5bbf-f1ec-ce15ae330efc"],"package_ndc":["43598-125-11"],"product_ndc":["43598-125"],"generic_name":["ERIBULIN MESYLATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ERIBULIN MESYLATE"],"manufacturer_name":["Dr. Reddys Laboratories Inc"],"application_number":["ANDA217473"],"is_original_packager":[true]},"version":"5","pregnancy":["8.1 Pregnancy Risk Summary Based on findings from an animal reproduction study and its mechanism of action, eribulin mesylate, can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )]. There are no available data on the use of eribulin mesylate during pregnancy. In an animal reproduction study, eribulin mesylate caused embryo-fetal toxicity when administered to pregnant rats during organogenesis at doses below the recommended human dose [see Data] . Advise pregnant women of the potential risk to a fetus. The estimated background risks of major birth defects and miscarriage for the indicated populations are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryo-fetal developmental toxicity study, pregnant rats received intravenous infusion of eribulin mesylate during organogenesis (Gestation Days 8, 10, and 12) at doses approximately 0.04, 0.13, 0.43 and 0.64 times the recommended human dose, based on body surface area. Increased abortion and severe fetal external or soft tissue malformations, including the absence of a lower jaw and tongue, or stomach and spleen, were observed at doses 0.64 times the recommended human dose of 1.4 mg/m 2 based on body surface area. Increased embryo-fetal death/resorption, reduced fetal weights, and minor skeletal anomalies consistent with developmental delay were also reported at doses at or above a maternally toxic dose of approximately 0.43 times the recommended human dose."],"overdosage":["10 OVERDOSAGE Overdosage of eribulin mesylate has been reported at approximately 4 times the recommended dose, which resulted in Grade 3 neutropenia lasting seven days and a Grade 3 hypersensitivity reaction lasting one day. There is no known antidote for eribulin mesylate injection overdose."],"description":["11 DESCRIPTION Eribulin mesylate injection contains eribulin mesylate, a microtubule dynamics inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai. The chemical name for eribulin mesylate is 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15Hfuro[3,2-i]furo[2',3':5,6]pyrano[4,3-b] [1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl] hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS, 15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (salt). It has a molecular weight of 826.01 (729.90 for free base). The molecular formula is C 40 H 59 NO 11 •CH 4 O 3 S. Eribulin mesylate has the following structural formula: Eribulin mesylate injection is a clear, colorless, sterile solution for intravenous administration. Each single-dose vial contains 1 mg of eribulin mesylate in 2 mL of solution. Each mL of solution contains 0.5 mg of eribulin mesylate (equivalent to 0.44 mg eribulin) in dehydrated alcohol (5% v/v) and water for injection (95% v/v). Sodium hydroxide or hydrochloric acid may be used for pH adjustment."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING NDC 43598-125-11 Injection: 1 mg/2 mL, in a single-dose vial. One vial per carton. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Do not freeze or refrigerate. Store the vials in their original cartons. Eribulin mesylate injection is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Discard unused portion."],"geriatric_use":["8.5 Geriatric Use Study 1 did not include sufficient numbers of subjects with metastatic breast cancer aged 65 years and older to determine whether they respond differently from younger subjects. Of the 827 subjects who received the recommended dose and schedule of eribulin mesylate in clinical studies with advanced breast cancer, 15% (121/827) were 65 and older and 2% (17/827) patients were 75 and older. No overall differences in safety were observed between these subjects and younger subjects. Clinical studies of eribulin mesylate did not include a sufficient number of subjects in Study 2 aged 65 years and older to determine whether they respond differently from younger subjects."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of eribulin mesylate injection in pediatric patients have not been established. Pediatric use information describing clinical studies in which efficacy was not demonstrated is approved for Eisai Inc’s HALAVEN ® (eribulin mesylate) injection. However, due to Eisai Inc’s marketing exclusivity rights, this drug product is not labeled with that information."],"effective_time":"20260120","nursing_mothers":["8.3 Females and Males of Reproductive Potential Contraception Females Based on findings from an animal reproduction study and its mechanism of action, eribulin mesylate can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for at least 2 weeks following the final dose . Males Based on its mechanism of action, advise males with female partners of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for 3.5 months following the final dose. Infertility Males Based on animal data, eribulin mesylate may result in damage to male reproductive tissues leading to impaired fertility of unknown duration [see Nonclinical Toxicology ( 13.1 )]."],"clinical_studies":["14 CLINICAL STUDIES 14.1 Metastatic Breast Cancer Study 1 was an open-label, randomized, multicenter trial of 762 patients with metastatic breast cancer who received at least two chemotherapeutic regimens for the treatment of metastatic disease and experienced disease progression within 6 months of their last chemotherapeutic regimen. Patients were required to receive prior anthracycline- and taxane-based chemotherapy for adjuvant or metastatic disease. Patients were randomized (2:1) to receive eribulin mesylate (n=508) or a single agent therapy selected prior to randomization (control arm, n=254). Randomization was stratified by geographic region, HER2/neu status, and prior capecitabine exposure. Eribulin mesylate was administered at a dose of 1.4 mg/m 2 on Days 1 and 8 of a 21‑day cycle. Eribulin mesylate-treated patients received a median of 5 cycles (range: 1 to 23 cycles) of therapy. Control arm therapy consisted of 97% chemotherapy (26% vinorelbine, 18% gemcitabine, 18% capecitabine, 16% taxane, 9% anthracycline, 10% other chemotherapy), and 3% hormonal therapy. The main efficacy outcome was overall survival. Patient demographic and baseline characteristics were comparable between the treatment arms. The median age was 55 (range: 27 to 85 years) and 92% were White. Sixty-four percent of patients were enrolled in North America/Western Europe/Australia, 25% in Eastern Europe/Russia, and 11% in Latin America/South Africa. Ninety-one percent of patients had a baseline ECOG performance status of 0 or 1. Tumor prognostic characteristics, including estrogen receptor status (positive: 67%, negative: 28%), progesterone receptor status (positive: 49%, negative: 39%), HER2/neu receptor status (positive: 16%, negative: 74%), triple negative status (ER - , PR - , HER2/neu - : 19%), presence of visceral disease (82%, including 60% liver and 38% lung) and bone disease (61%), and number of sites of metastases (greater than two: 50%), were also similar in the eribulin mesylate and control arms. Patients received a median of four prior chemotherapy regimens in both arms. In Study 1, a statistically significant improvement in overall survival was observed in patients randomized to the eribulin mesylate arm compared to the control arm (see Table 5). An updated, unplanned survival analysis, conducted when 77% of events had been observed (see Figure 1), was consistent with the primary analysis. In patients randomized to eribulin mesylate, the objective response rate by the RECIST criteria was 11% (95% CI: 8.6%, 14.3%) and the median response duration was 4.2 months (95% CI: 3.8, 5.0 months). Table 5: Comparison of Overall Survival in Eribulin Mesylate and Control Arm - Study 1 Overall Survival Eribulin Mesylate (n=508) Control Arm (n=254) Primary survival analysis Number of deaths 274 148 Median, months (95% CI) 13.1 (11.8, 14.3) 10.6 (9.3, 12.5) Hazard Ratio (95% CI) a 0.81 (0.66, 0.99) P value b 0.041 Updated survival analysis Number of deaths 386 203 Median, months (95% CI) 13.2 (12.1, 14.4) 10.6 (9.2, 12.0) CI = confidence interval a Based on Cox proportional hazards model stratified by geographic region, HER2 status,and prior capecitabine therapy. b Based on a log-rank test stratified by geographic region, HER2 status, and prior capecitabine therapy. Figure 1: Updated Overall Survival Analysis for Study 1 14.2 Liposarcoma The efficacy and safety of eribulin mesylate were evaluated in Study 2, an open-label, randomized (1:1), multicenter, active-controlled trial. Eligible patients were required to have unresectable, locally advanced or metastatic liposarcoma or leiomyosarcoma, at least two prior systemic chemotherapies (one of which must have included an anthracycline), and disease progression within 6 months of the most recent chemotherapy regimen. Patients were randomized to eribulin mesylate 1.4 mg/m 2 administered intravenously on Days 1 and 8 of a 21‑day cycle or to dacarbazine at a dose of 850 mg/m 2 , 1,000 mg/m 2 , or 1,200 mg/m 2 administered intravenously every 21 days (dacarbazine dose was selected by the investigator prior to randomization). Treatment continued until disease progression or unacceptable toxicity. Randomization was stratified by histology (liposarcoma or leiomyosarcoma), number of prior therapies (2 vs. > 2), and geographic region (U.S. and Canada vs. Western Europe, Australia, and Israel vs. Eastern Europe, Latin America, and Asia). The major efficacy outcome measure was overall survival (OS). Additional efficacy outcome measures were progression-free survival (PFS) and confirmed objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Patients in the dacarbazine arm were not offered eribulin mesylate at the time of disease progression. A total of 446 patients were randomized, 225 to the eribulin mesylate arm and 221 to the dacarbazine arm. The median age was 56 years (range: 24 to 83); 33% were male; 73% were White; 44% had ECOG performance status (PS) 0 and 53% had ECOG PS 1; 68% had leiomyosarcoma and 32% had liposarcoma; 39% were enrolled in U.S. and Canada (Region 1) and 46% were enrolled in Western Europe, Australia, and Israel (Region 2); and 47% received more than two prior systemic chemotherapies. The most common (>40%) prior systemic chemotherapies were doxorubicin (90%), ifosfamide (62%), gemcitabine (59%), trabectedin (50%), and docetaxel (48%). Of the 143 patients with liposarcoma, the median age was 55 years (range: 32 to 83); 62% were male, 72% were White; 41% had ECOG PS of 0 and 53% had ECOG PS of 1; 35% were enrolled in Region 1 and 51% were enrolled in Region 2; and 44% received more than two prior systemic chemotherapies. The distribution of subtypes of liposarcoma, based on local histologic assessment, were 45% dedifferentiated, 37% myxoid/round cell, and 18% pleomorphic. Study 2 demonstrated a statistically significant improvement in OS in patients randomized to eribulin mesylate compared with dacarbazine (see Table 6). There was no significant difference in progression-free survival in the overall population. Treatment effects of eribulin mesylate were limited to patients with liposarcoma based on pre-planned, exploratory subgroup analyses of OS and PFS (see Tables 6 and 7 and Figure 2). There was no evidence of efficacy of eribulin mesylate in patients with advanced or metastatic leiomyosarcoma in Study 2 (see Table 7). Table 6: Efficacy Results for the Liposarcoma Stratum and All Patients* in Study 2 a Liposarcoma Stratum All Patients* Eribulin Mesylate (n=71) Dacarbazine (n=72) Eribulin Mesylate (n=225) Dacarbazine (n=221) Overall survival Deaths, n (%) 52 (73) 63 (88) 173 (77) 179 (81) Median, months (95% CI) 15.6 (10.2, 18.6) 8.4 (5.2, 10.1) 13.5 (11.1, 16.5) 11.3 (9.5, 12.6) Hazard ratio (HR)(95% CI) 0.51 (0.35, 0.75) 0.75 (0.61, 0.94) Stratified log-rank p value N/A † 0.011 Progression-free survival Events, n (%) 57 (80) 59 (82) 194 (86) 185 (84) Disease progression 53 52 180 170 Death 4 7 14 15 Median, months (95% CI) 2.9 (2.6, 4.8) 1.7 (1.4, 2.6) 2.6 (2.0, 2.8) 2.6 (1.7, 2.7) HR(95% CI) 0.52(0.35, 0.78) 0.86 (0.69, 1.06) Objective response rate Objective response rate (%)(95% CI) 1.4 (0, 7.6) 0 (0, 4.2) 4.0 (1.8, 7.5) 5.0 (2.5, 8.7) a Efficacy data from one study site enrolling six patients were excluded. *All patients = liposarcoma and leiomyosarcoma. † N/A = not applicable Figure 2: Kaplan-Meier Curves of Overall Survival in the Liposarcoma Stratum in Study 2 Table 7: Efficacy Results for the Leiomyosarcoma Stratum in Study 2 a Leiomyosarcoma Stratum Eribulin Mesylate (n=154) Dacarbazine (n=149) Overall survival Deaths, n (%) 121 (79) 116 (78) Median, months (95%CI) 12.8 (10.3, 14.8) 12.3 (11.0, 15.1) HR (95% CI) 0.90 (0.69, 1.18) Progression-free survival Events, n (%) 137 (89) 126 (85) Disease progression 127 118 Death 10 8 Median, months (95% CI) 2.2 (1.5, 2.7) 2.6 (2.2, 2.9) HR (95% CI) 1.05 (0.81, 1.35) Objective response rate (%)(95% CI) 5.2 (2.3, 10) 7.4 (3.7, 12.8) a Efficacy data from one study site enrolling six patients were excluded."],"pharmacodynamics":["12.2 Pharmacodynamics Cardiac Electrophysiology The effect of eribulin mesylate on the QTc interval was assessed in an open-label, uncontrolled, multicenter, single-arm dedicated QT trial. A total of 26 patients with solid tumors received 1.4 mg/m 2 of eribulin mesylate on Days 1 and 8 of a 21-day cycle. A delayed QTc prolongation was observed on Day 8, with no prolongation observed on Day 1. The maximum mean QTcF change from baseline (95% upper confidence interval) was 11.4 (19.5) ms."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics (PK) of eribulin is linear with a mean elimination half-life of approximately 40 hours, a mean volume of distribution of 43 L/m 2 to 114 L/m 2 and mean clearance of 1.16 L/hr/m 2 to 2.42 L/hr/m 2 over the dose range of 0.25 mg/m 2 to 4.0 mg/m 2 . The human plasma protein binding of eribulin at concentrations of 100 ng/mL to 1,000 ng/mL ranges from 49% to 65%. Eribulin exposure after multiple dosing is comparable to that following a single dose. No accumulation of eribulin is observed with weekly administration. Elimination Metabolism Unchanged eribulin was the major circulating species in plasma following administration of 14 C‑eribulin to patients. Metabolite concentrations represented <0.6% of parent compound, confirming that there are no major human metabolites of eribulin. Cytochrome P450 3A4 (CYP3A4) negligibly metabolizes eribulin in vitro . Excretion Eribulin is eliminated primarily in feces unchanged. After administration of 14 C-eribulin to patients, approximately 82% of the dose was eliminated in feces and 9% in urine. Unchanged eribulin accounted for approximately 88% and 91% of total eribulin in feces and urine, respectively. Specific Populations Age, Sex, and Race/Ethnicity: Based on a population pharmacokinetic analysis, no clinically meaningful differences in the pharmacokinetics of eribulin were observed based on age, sex, or race. Hepatic Impairment In a study evaluating the effect of hepatic impairment on the PK of eribulin, eribulin exposures increased by 1.8-fold in patients with mild hepatic impairment (Child-Pugh A; n=7) and by 2.5‑fold in patients with moderate (Child-Pugh B; n=5) hepatic impairment as compared to patients with normal hepatic function (n=6). Administration of eribulin mesylate at a dose of 1.1 mg/m 2 to patients with mild hepatic impairment and 0.7 mg/m 2 to patients with moderate hepatic impairment resulted in similar exposure to eribulin at a dose of 1.4 mg/m 2 to patients with normal hepatic function [see Dosage and Administration ( 2.1 ), Use in Specific Populations ( 8.6 )]. Renal Impairment In a study evaluating the effect of renal impairment on the PK of eribulin, patients with moderate (CLcr 30 to 49 mL/min; n=7) and severe renal impairment (CLcr 15 to 29 mL/min; n=6) had 1.5-fold higher eribulin dose-normalized exposures compared to that in patients with normal renal function (CLcr ≥ 80 mL/min; n=6). There were no clinically meaningful changes in patients with mild renal impairment (CLcr 50 to 79 mL/min; n=27) [see Dosage and Administration ( 2.1 ), Use in Specific Populations ( 8.7) ]. Drug Interaction Studies Effect of Strong Inhibitors or Inducers of CYP3A4 on Eribulin: The effect of a strong CYP3A4 inhibitor and a P-gp inhibitor, ketoconazole, on the PK of eribulin was studied in a crossover trial of 12 patients with advanced solid tumors. No clinically relevant PK interaction was observed when eribulin mesylate was administered with or without ketoconazole (the geometric mean ratio of the AUC: 0.97; 90% CI: 0.83, 1.12). The effect of a CYP3A4 inducer, rifampin, on the PK of eribulin was studied in a crossover trial of 14 patients with advanced solid tumors. No clinically relevant PK interaction was observed when eribulin mesylate was administered with or without rifampin (the geometric mean ratio of the AUC: 1.10; 90 CI%: 0.91, 1.34). Effect of Eribulin on CYP Substrates : Eribulin shows no induction potential for CYP1A, CYP2B6, CYP2C9, CYP2C19, and CYP3A in primary human hepatocytes. Eribulin inhibits CYP3A4 activity in human liver microsomes, but it is unlikely that eribulin will substantially increase the plasma levels of CYP3A4 substrates. No significant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP2E1 was detected with eribulin concentrations up to 5 μM in pooled human liver microsomes. In vitro drug interaction studies indicate that eribulin does not inhibit drugs that are substrates of these enzymes and it is unlikely that eribulin will affect plasma levels of drugs that are substrates of CYP enzymes. Effect of Transporters on Eribulin: In vitro data suggest that eribulin at clinically relevant concentrations is a substrate of P-gp, but is not a substrate of breast cancer resistance protein (BCRP), multidrug resistance proteins (MRP2, MRP4), bile salt extrusion pump (BSEP), organic anion transporting polypeptides (OATP1B1, OATP1B3), organic anion transporters (OAT1, OAT3), organic cation transporters (OCT1, OCT2), or multidrug and toxin extrusion 1 (MATE1). Effect of Eribulin on Transporters: In vitro data suggest that eribulin at clinically relevant concentrations may inhibit P-gp, but does not inhibit BCRP, OATP1B1, OCT1, OAT1, OAT3, or MATE1."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions (≥25%) in metastatic breast cancer were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. ( 6.1 ) The most common adverse reactions (≥25%) in liposarcoma and leiomyosarcoma were fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, and pyrexia. The most common (≥5%) Grade 3 to 4 laboratory abnormalities in liposarcoma and leiomyosarcoma were neutropenia, hypokalemia, and hypocalcemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories, Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice. The following adverse reactions are discussed in detail in other sections of the labeling: Neutropenia [see Warnings and Precautions ( 5.1) ] Peripheral neuropathy [see Warnings and Precautions (5.2) ] QT prolongation [see Warnings and Precautions (5.4) ] In clinical trials, eribulin mesylate has been administered to 1,963 patients including 467 patients exposed to eribulin mesylate for 6 months or longer. The majority of the 1,963 patients were women (92%) with a median age of 55 years (range: 17 to 85 years). The racial and ethnic distribution was White (72%), Black (4%), Asian (9%), and other (3%). Metastatic Breast Cancer The most common adverse reactions (≥25%) reported in patients receiving eribulin mesylate were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. The most common serious adverse reactions reported in patients receiving eribulin mesylate were febrile neutropenia (4%) and neutropenia (2%). The most common adverse reaction resulting in discontinuation of eribulin mesylate was peripheral neuropathy (5%). The adverse reactions described in Table 2 were identified in 750 patients treated in Study 1 [see Clinical Studies ( 14.1 )] . In Study 1, patients were randomized (2:1) to receive either eribulin mesylate (1.4 mg/m 2 on Days 1 and 8 of a 21-day cycle) or single agent treatment chosen by their physician (control group). A total of 503 patients received eribulin mesylate and 247 patients in the control group received therapy consisting of chemotherapy [total 97% (anthracyclines 10%, capecitabine 18%, gemcitabine 19%, taxanes 15%, vinorelbine 25%, other chemotherapies 10%)] or hormonal therapy (3%). The median duration of exposure was 118 days for patients receiving eribulin mesylate and 63 days for patients receiving control therapy. Table 2 reports the most common adverse reactions occurring in at least 10% of patients in either group. Table 2: Adverse Reactions a with a Per-Patient Incidence of at Least 10% in Study 1 Adverse Reactions Eribulin Mesylate n=503 Control Group n=247 All Grades ≥ Grade 3 All Grades ≥ Grade 3 Blood and lymphatic system disorders b Neutropenia 82% 57% 53% 23% Anemia 58% 2% 55% 4% Nervous system disorders Peripheral neuropathy c 35% 8% 16% 2% Headache 19% <1% 12% <1% General disorders Asthenia/Fatigue 54% 10% 40% 11% Pyrexia 21% <1% 13% <1% Mucosalinflammation 9% 1% 10% 2% Gastrointestinal disorders Nausea 35% 1% 28% 3% Constipation 25% 1% 21% 1% Vomiting 18% 1% 18% 1% Diarrhea 18% 0 18% 0 Musculoskeletal and connective tissue disorders Arthralgia/Myalgia 22% <1% 12% 1% Back pain 16% 1% 7% 2% Bone pain 12% 2% 9% 2% Pain in extremity 11% 1% 10% 1% Metabolism and nutrition disorders Decreased weight 21% 1% 14% <1% Anorexia 20% 1% 13% 1% Respiratory, thoracic, and mediastinal disorders Dyspnea 16% 4% 13% 4% Cough 14% 0 9% 0 Skin and subcutaneous tissue disorders Alopecia 45% NA d 10% NA d Infections Urinary Tract Infection 10% 1% 5% 0 a. adverse reactions were graded per National Cancer Institute Criteria for Adverse Events version 4.0. b based upon laboratory data c includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motorneuropathy, polyneuropathy, peripheral sensory neuropathy, and paraesthesia. d not applicable; (grading system does not specify > Grade 2 for alopecia). Cytopenias: Grade 3 neutropenia occurred in 28% (143/503) of patients who received eribulin mesylate in Study 1, and 29% (144/503) of patients experienced Grade 4 neutropenia. Febrile neutropenia occurred in 5% (23/503) of patients; two patients (0.4%) died from complications of febrile neutropenia. Dose reduction due to neutropenia was required in 12% (62/503) of patients and discontinuation was required in <1% of patients. The mean time to nadir was 13 days and the mean time to recovery from severe neutropenia (<500/mm 3 ) was 8 days. Grade 3 or greater thrombocytopenia occurred in 1% (7/503) of patients. G-CSF (granulocyte colony-stimulating factor) or GM-CSF (granulocyte–macrophage colony-stimulating factor) was used in 19% of patients who received eribulin mesylate. Peripheral Neuropathy : In Study 1, 17% of enrolled patients had Grade 1 peripheral neuropathy and 3% of patients had Grade 2 peripheral neuropathy at baseline. Dose reduction due to peripheral neuropathy was required by 3% (14/503) of patients who received eribulin mesylate. Four percent (20/503) of patients experienced peripheral motor neuropathy of any grade and 2% (8/503) of patients developed Grade 3 peripheral motor neuropathy. Liver Function Test Abnormalities : Among patients with Grade 0 or 1 ALT levels at baseline, 18% of eribulin mesylate-treated patients experienced Grade 2 or greater ALT elevation. One eribulin mesylate-treated patient without documented liver metastases had concomitant Grade 2 elevations in bilirubin and ALT; these abnormalities resolved and did not recur with re-exposure to eribulin mesylate. Less Common Adverse Reactions: The following additional adverse reactions were reported in ≥5% to <10% of the eribulin mesylate-treated group: Eye Disorders: increased lacrimation Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth General Disorders and Administration Site Conditions: peripheral edema Infections and Infestations: upper respiratory tract infection Metabolism and Nutrition Disorders: hypokalemia Musculoskeletal and Connective Tissue Disorders: muscle spasms, muscular weakness Nervous System Disorders: dysgeusia, dizziness Psychiatric Disorders: insomnia, depression· Skin and Subcutaneous Tissue Disorders: rash Liposarcoma The safety of eribulin mesylate was evaluated in Study 2, an open-label, randomized, multicenter, active-controlled trial, in which patients were randomized (1:1) to receive either eribulin mesylate 1.4 mg/m 2 on Days 1 and 8 of a 21-day cycle or dacarbazine at doses of 850 mg/m 2 (20%), 1,000 mg/m 2 (64%), or 1,200 mg/m 2 (16%) every 3 weeks. A total of 223 patients received eribulin mesylate and 221 patients received dacarbazine. Patients were required to have received at least two prior systemic chemotherapy regimens. The trial excluded patients with pre-existing ≥ Grade 3 peripheral neuropathy, known central nervous system metastasis, elevated serum bilirubin or significant chronic liver disease, history of myocardial infarction within 6 months, history of New York Heart Association Class II or IV heart failure, or cardiac arrhythmia requiring treatment. The median age of the safety population in Study 2 was 56 years (range: 24 to 83 years); 67% female; 73% White, 3% Black or African American, 8% Asian/Pacific Islander, and 15% unknown; 99% received prior anthracycline-containing regimen; and 99% received ≥ 2 prior regimens. The median duration of exposure was 2.3 months (range: 21 days to 26 months) for patients receiving eribulin mesylate [see Clinical Studies ( 14.2 )]. The most common adverse reactions (≥25%) reported in patients receiving eribulin mesylate were fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, and pyrexia. The most common (≥5%) Grade 3 to 4 laboratory abnormalities reported in patients receiving eribulin mesylate were neutropenia, hypokalemia, and hypocalcemia. The most common serious adverse reactions reported in patients receiving eribulin mesylate were neutropenia (4.9%) and pyrexia (4.5%). Permanent discontinuation of eribulin mesylate for adverse reactions occurred in 8% of patients. The most common adverse reactions resulting in discontinuation of eribulin mesylate were fatigue and thrombocytopenia (0.9% each). Twenty-six percent of patients required at least one dose reduction. The most frequent adverse reactions that led to dose reduction were neutropenia (18%) and peripheral neuropathy (4.0%). Table 3 summarizes the incidence of adverse reactions occurring in at least 10% of patients in the eribulin mesylate-treated arm in Study 2. Table 3: Adverse Reactions a Occurring in ≥10% (all Grades) of Patients Treated on the Eribulin Mesylate arm and at a Higher Incidence than in the Dacarbazine Arm (Between Arm Difference of ≥5% for All Grades or ≥2% for Grades 3 and 4) (Study 2) b Adverse Reaction Eribulin Mesylate n=223 Dacarbazine n=221 All Grades Grades 3 to 4 All Grades Grades 3 to 4 Nervous system disorders Peripheral Neuropathy c 29% 3.1% 8% 0.5% Headache 18% 0% 10% 0% General disorders Pyrexia 28% 0.9% 14% 0.5% Gastrointestinal disorders Constipation 32% 0.9% 26% 0.5% Abdominal pain d 29% 1.8% 23% 4.1% Stomatitis 14% 0.9% 5% 0.5% Skin and subcutaneous tissue disorders Alopecia 35% NA e 2.7% NA e Infections Urinary tract infection 11% 2.2% 5% 0.5% a Adverse reactions were graded per National Cancer Institute Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03). b Safety data from one study site enrolling six patients were excluded. c Includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensory neuropathy, and paraesthesia. d Includes abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort. e Not applicable; (grading system does not specify > Grade 2 for alopecia). Other clinically important adverse reactions occurring in ≥10% of the eribulin mesylate-treated patients were: Gastrointestinal Disorders: nausea (41%); vomiting (19%), diarrhea (17%) General Disorders: asthenia/fatigue (62%); peripheral edema (12%) Metabolism and Nutrition Disorders: decreased appetite (19%) Musculoskeletal and Connective Tissue Disorders: arthralgia/myalgia (16%); back pain (16%) Respiratory Disorders: cough (18%) Less Common Adverse Reactions: The following additional clinically important adverse reactions were reported in ≥5% to <10% of the eribulin mesylate-treated group: Blood and Lymphatic System Disorders: thrombocytopenia Eye Disorders: increased lacrimation Gastrointestinal Disorders: dyspepsia Metabolism and Nutrition Disorders: hyperglycemia Musculoskeletal and Connective Tissue Disorders: muscle spasms, musculoskeletal pain Nervous System Disorders: dizziness, dysgeusia Psychiatric Disorders: insomnia, anxiety Respiratory, Thoracic, and Mediastinal Disorders: oropharyngeal pain Vascular Disorders: hypotension Table 4: Laboratory Abnormalities Occurring in ≥10% (all Grades) of Patients Treated on the Eribulin Mesylate arm and at a Higher Incidence than in the Dacarbazine Arm (Between Arm Difference of ≥5% for All Grades or ≥2% for Grades 3 and 4) a (Study 2) † Laboratory Abnormality Eribulin Mesylate Dacarbazine All Grades Grades 3 to 4 All Grades Grades 3 to 4 Hematology Anemia 70% 4.1% 52% 6% Neutropenia 63% 32% 30% 8.9% Chemistry Increased alanine aminotransferase (ALT) 43% 2.3% 28% 2.3% Increased aspartate aminotransferase (AST) 36% 0.9% 16% 0.5% Hypokalemia 30% 5.4% 14% 2.8% Hypocalcemia 28% 5% 18% 1.4% Hypophosphatemia 20% 3.2% 11% 1.4% a Each test incidence is based on the number of patients who had both baseline and at least one on-study measurement and at least 1 grade increase from baseline. Eribulin mesylate group (range221 to 222) and dacarbazine group (range 214 to 215). † Laboratory results were graded per NCI CTCAE v4.03. 6.2 Postmarketing Experience The following adverse drug reactions have been identified during post-approval use of eribulin mesylate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders: lymphopenia Gastrointestinal Disorders: pancreatitis Hepatobiliary Disorders: hepatotoxicity Immune System Disorders: drug hypersensitivity Infections and Infestations: pneumonia, sepsis/neutropenic sepsis Metabolism and Nutrition Disorders: hypomagnesemia, dehydration Respiratory, thoracic and mediastinal disorders: interstitial lung disease Skin and Subcutaneous Tissue Disorders: pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis"],"contraindications":["4 CONTRAINDICATIONS None. None ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Effects of Other Drugs on Eribulin Mesylate No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P‑glycoprotein (P-gp) inhibitors. Clinically meaningful differences in exposure (AUC) were not observed in patients with advanced solid tumors when eribulin mesylate was administered with or without ketoconazole (a strong inhibitor of CYP3A4 and a P-gp inhibitor) and when eribulin mesylate was administered with or without rifampin (a CYP3A4 inducer) [see Clinical Pharmacology ( 12.3 )]. 7.2 Effects of Eribulin Mesylate on Other Drugs Eribulin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 enzymes or induce CYP1A2, CYP2C9, CYP2C19 or CYP3A4 enzymes at relevant clinical concentrations. Eribulin is not expected to alter the plasma concentrations of drugs that are substrates of these enzymes [see Clinical Pharmacology ( 12.3 )]."],"labor_and_delivery":["8.2 Lactation Risk Summary There is no information regarding the presence of eribulin mesylate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. No lactation studies in animals were conducted. Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with eribulin mesylate injection and for 2 weeks after the final dose."],"mechanism_of_action":["12.1 Mechanism of Action Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G 2 /M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. In addition, eribulin treatment of human breast cancer cells caused changes in morphology and gene expression as well as decreased migration and invasiveness in vitro . In mouse xenograft models of human breast cancer, eribulin treatment was associated with increased vascular perfusion and permeability in the tumor cores, resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G 2 /M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. In addition, eribulin treatment of human breast cancer cells caused changes in morphology and gene expression as well as decreased migration and invasiveness in vitro . In mouse xenograft models of human breast cancer, eribulin treatment was associated with increased vascular perfusion and permeability in the tumor cores, resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype. 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of eribulin mesylate on the QTc interval was assessed in an open-label, uncontrolled, multicenter, single-arm dedicated QT trial. A total of 26 patients with solid tumors received 1.4 mg/m 2 of eribulin mesylate on Days 1 and 8 of a 21-day cycle. A delayed QTc prolongation was observed on Day 8, with no prolongation observed on Day 1. The maximum mean QTcF change from baseline (95% upper confidence interval) was 11.4 (19.5) ms. 12.3 Pharmacokinetics The pharmacokinetics (PK) of eribulin is linear with a mean elimination half-life of approximately 40 hours, a mean volume of distribution of 43 L/m 2 to 114 L/m 2 and mean clearance of 1.16 L/hr/m 2 to 2.42 L/hr/m 2 over the dose range of 0.25 mg/m 2 to 4.0 mg/m 2 . The human plasma protein binding of eribulin at concentrations of 100 ng/mL to 1,000 ng/mL ranges from 49% to 65%. Eribulin exposure after multiple dosing is comparable to that following a single dose. No accumulation of eribulin is observed with weekly administration. Elimination Metabolism Unchanged eribulin was the major circulating species in plasma following administration of 14 C‑eribulin to patients. Metabolite concentrations represented <0.6% of parent compound, confirming that there are no major human metabolites of eribulin. Cytochrome P450 3A4 (CYP3A4) negligibly metabolizes eribulin in vitro . Excretion Eribulin is eliminated primarily in feces unchanged. After administration of 14 C-eribulin to patients, approximately 82% of the dose was eliminated in feces and 9% in urine. Unchanged eribulin accounted for approximately 88% and 91% of total eribulin in feces and urine, respectively. Specific Populations Age, Sex, and Race/Ethnicity: Based on a population pharmacokinetic analysis, no clinically meaningful differences in the pharmacokinetics of eribulin were observed based on age, sex, or race. Hepatic Impairment In a study evaluating the effect of hepatic impairment on the PK of eribulin, eribulin exposures increased by 1.8-fold in patients with mild hepatic impairment (Child-Pugh A; n=7) and by 2.5‑fold in patients with moderate (Child-Pugh B; n=5) hepatic impairment as compared to patients with normal hepatic function (n=6). Administration of eribulin mesylate at a dose of 1.1 mg/m 2 to patients with mild hepatic impairment and 0.7 mg/m 2 to patients with moderate hepatic impairment resulted in similar exposure to eribulin at a dose of 1.4 mg/m 2 to patients with normal hepatic function [see Dosage and Administration ( 2.1 ), Use in Specific Populations ( 8.6 )]. Renal Impairment In a study evaluating the effect of renal impairment on the PK of eribulin, patients with moderate (CLcr 30 to 49 mL/min; n=7) and severe renal impairment (CLcr 15 to 29 mL/min; n=6) had 1.5-fold higher eribulin dose-normalized exposures compared to that in patients with normal renal function (CLcr ≥ 80 mL/min; n=6). There were no clinically meaningful changes in patients with mild renal impairment (CLcr 50 to 79 mL/min; n=27) [see Dosage and Administration ( 2.1 ), Use in Specific Populations ( 8.7) ]. Drug Interaction Studies Effect of Strong Inhibitors or Inducers of CYP3A4 on Eribulin: The effect of a strong CYP3A4 inhibitor and a P-gp inhibitor, ketoconazole, on the PK of eribulin was studied in a crossover trial of 12 patients with advanced solid tumors. No clinically relevant PK interaction was observed when eribulin mesylate was administered with or without ketoconazole (the geometric mean ratio of the AUC: 0.97; 90% CI: 0.83, 1.12). The effect of a CYP3A4 inducer, rifampin, on the PK of eribulin was studied in a crossover trial of 14 patients with advanced solid tumors. No clinically relevant PK interaction was observed when eribulin mesylate was administered with or without rifampin (the geometric mean ratio of the AUC: 1.10; 90 CI%: 0.91, 1.34). Effect of Eribulin on CYP Substrates : Eribulin shows no induction potential for CYP1A, CYP2B6, CYP2C9, CYP2C19, and CYP3A in primary human hepatocytes. Eribulin inhibits CYP3A4 activity in human liver microsomes, but it is unlikely that eribulin will substantially increase the plasma levels of CYP3A4 substrates. No significant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP2E1 was detected with eribulin concentrations up to 5 μM in pooled human liver microsomes. In vitro drug interaction studies indicate that eribulin does not inhibit drugs that are substrates of these enzymes and it is unlikely that eribulin will affect plasma levels of drugs that are substrates of CYP enzymes. Effect of Transporters on Eribulin: In vitro data suggest that eribulin at clinically relevant concentrations is a substrate of P-gp, but is not a substrate of breast cancer resistance protein (BCRP), multidrug resistance proteins (MRP2, MRP4), bile salt extrusion pump (BSEP), organic anion transporting polypeptides (OATP1B1, OATP1B3), organic anion transporters (OAT1, OAT3), organic cation transporters (OCT1, OCT2), or multidrug and toxin extrusion 1 (MATE1). Effect of Eribulin on Transporters: In vitro data suggest that eribulin at clinically relevant concentrations may inhibit P-gp, but does not inhibit BCRP, OATP1B1, OCT1, OAT1, OAT3, or MATE1."],"indications_and_usage":["1 INDICATIONS AND USAGE Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) 1.1 Metastatic Breast Cancer Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting [see Clinical Studies ( 14.1 )]. 1.2 Liposarcoma Eribulin mesylate injection is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen [see Clinical Studies ( 14.2 )] ."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Neutropenia : Monitor peripheral blood cell counts and adjust dose as appropriate. ( 5.1 ) Peripheral Neuropathy : Monitor for signs of neuropathy. Manage with dose delay and adjustment. ( 5.2 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. ( 5.3 , 8.1 , 8.3 ) QT Prolongation : Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid in patients with congenital long QT syndrome. ( 5.4 ) 5.1 Neutropenia In Study 1, severe neutropenia (ANC < 500/mm 3 ) lasting more than one week occurred in 12% (62/503) of patients with metastatic breast cancer, leading to discontinuation in <1% of patients. Febrile neutropenia (fever ≥38.5°C with Grade 3 or 4 neutropenia) occurred in 5% (23/503) of patients; two patients (0.4%) died from complications of febrile neutropenia [see Adverse Reactions ( 6.1 )] . In Study 1, patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × ULN (upper limit of normal) experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal aminotransferase levels. Patients with bilirubin > 1.5 × ULN also had a higher incidence of Grade 4 neutropenia and febrile neutropenia. In Study 2, severe neutropenia (ANC < 500/mm 3 ) lasting more than one week occurred in 12% (26/222) of patients with liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 0.9% of patients treated with eribulin mesylate and fatal neutropenic sepsis in 0.9% [see Adverse Reactions ( 6.1 )]. Monitor complete blood counts prior to each dose; increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration of eribulin mesylate injection and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting longer than 7 days [see Dosage and Administration ( 2.2 )]. Clinical studies of eribulin mesylate did not include patients with baseline neutrophil counts below 1,500/mm 3 . 5.2 Peripheral Neuropathy In Study 1, Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients with metastatic breast cancer (MBC). Peripheral neuropathy was the most common toxicity leading to discontinuation of eribulin mesylate (5% of patients; 24/503) in Study 1. Neuropathy lasting more than one year occurred in 5% (26/503) of patients. Twenty-two percent (109/503) of patients developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25 to 662 days). In Study 2, Grade 3 peripheral neuropathy occurred in 3.1% (7/223) of eribulin mesylate-treated patients. Peripheral neuropathy led to discontinuation of eribulin mesylate in 0.9% of patients. The median time to first occurrence of peripheral neuropathy of any severity was 5 months (range: 3.5 months to 9 months). Neuropathy lasting more than 60 days occurred in 58% (38/65) of patients. Sixty three percent (41/65) had not recovered within a median follow-up duration of 6.4 months (range: 27 days to 29 months). Monitor patients closely for signs of peripheral motor and sensory neuropathy. Withhold eribulin mesylate in patients who experience Grade 3 or 4 peripheral neuropathy, until resolution to Grade 2 or less [see Dosage and Administration ( 2.2 )] . 5.3 Embryo-Fetal Toxicity Based on findings from an animal reproduction study and its mechanism of action, eribulin mesylate can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of eribulin mesylate in pregnant women. In animal reproduction studies, eribulin mesylate caused embryo-fetal toxicity when administered to pregnant rats during organogenesis at doses below the recommended human dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for 3.5 months following the final dose [see Use in Specific Populations ( 8.1 )]. 5.4 QT Prolongation In an uncontrolled open-label ECG study in 26 patients, QT prolongation was observed on Day 8, independent of eribulin concentration, with no QT prolongation observed on Day 1. ECG monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating eribulin mesylate injection and monitor these electrolytes periodically during therapy. Avoid eribulin mesylate injection in patients with congenital long QT syndrome."],"clinical_studies_table":["<table frame=\"box\" rules=\"all\"><tbody><tr><td><content styleCode=\"bold\">Overall Survival</content></td><td align=\"center\"><content styleCode=\"bold\">Eribulin Mesylate</content><content styleCode=\"bold\"> (n=508)</content></td><td align=\"center\"><content styleCode=\"bold\">Control Arm </content><content styleCode=\"bold\"> (n=254)</content></td></tr><tr><td colspan=\"3\"><content styleCode=\"bold\">Primary survival analysis</content></td></tr><tr><td>Number of deaths</td><td align=\"center\">274</td><td align=\"center\">148</td></tr><tr><td>Median, months (95% CI)</td><td align=\"center\">13.1 (11.8, 14.3)</td><td align=\"center\">10.6 (9.3, 12.5)</td></tr><tr><td>Hazard Ratio (95% CI)<sup>a</sup></td><td align=\"center\" colspan=\"2\">0.81 (0.66, 0.99)</td></tr><tr><td>P value<sup>b</sup></td><td align=\"center\" colspan=\"2\">0.041</td></tr><tr><td colspan=\"3\"><content styleCode=\"bold\">Updated survival analysis</content></td></tr><tr><td>Number of deaths</td><td align=\"center\">386</td><td align=\"center\">203</td></tr><tr><td>Median, months (95% CI)</td><td align=\"center\">13.2 (12.1, 14.4)</td><td align=\"center\">10.6 (9.2, 12.0)</td></tr><tr><td colspan=\"3\">CI = confidence interval <sup>a</sup> Based on Cox proportional hazards model stratified by geographic region, HER2 status,and prior capecitabine therapy. <sup>b</sup> Based on a log-rank test stratified by geographic region, HER2 status, and prior capecitabine therapy.</td></tr></tbody></table>","<table frame=\"box\" rules=\"all\"><tbody><tr><td rowspan=\"2\"/><td align=\"center\" colspan=\"3\"><content styleCode=\"bold\">Liposarcoma</content><content styleCode=\"bold\">Stratum</content></td><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">All Patients*</content></td></tr><tr><td align=\"center\"><content styleCode=\"bold\">Eribulin Mesylate (n=71)</content></td><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Dacarbazine  (n=72)</content></td><td align=\"center\"><content styleCode=\"bold\">Eribulin Mesylate  (n=225)</content></td><td align=\"center\"><content styleCode=\"bold\">Dacarbazine  (n=221)</content></td></tr><tr><td colspan=\"6\"><content styleCode=\"bold\">Overall survival</content></td></tr><tr><td>Deaths, n (%)</td><td align=\"center\">52 (73)</td><td align=\"center\" colspan=\"2\">63 (88)</td><td align=\"center\">173 (77)</td><td align=\"center\">179 (81)</td></tr><tr><td>Median, months (95% CI)</td><td align=\"center\">15.6 (10.2, 18.6)</td><td align=\"center\" colspan=\"2\">8.4 (5.2, 10.1)</td><td align=\"center\">13.5 (11.1, 16.5)</td><td align=\"center\">11.3 (9.5, 12.6)</td></tr><tr><td>Hazard ratio (HR)(95% CI)</td><td align=\"center\" colspan=\"3\">0.51 (0.35, 0.75)</td><td align=\"center\" colspan=\"2\">0.75 (0.61, 0.94)</td></tr><tr><td>Stratified log-rank p value</td><td align=\"center\" colspan=\"3\">N/A<sup>&#x2020;</sup></td><td align=\"center\" colspan=\"2\">0.011</td></tr><tr><td colspan=\"6\"><content styleCode=\"bold\">Progression-free survival</content></td></tr><tr><td>Events, n (%)</td><td align=\"center\">57 (80)</td><td align=\"center\" colspan=\"2\">59 (82)</td><td align=\"center\">194 (86)</td><td align=\"center\">185 (84)</td></tr><tr><td>Disease progression</td><td align=\"center\">53</td><td align=\"center\" colspan=\"2\">52</td><td align=\"center\">180</td><td align=\"center\">170</td></tr><tr><td>Death</td><td align=\"center\">4</td><td align=\"center\" colspan=\"2\">7</td><td align=\"center\">14</td><td align=\"center\">15</td></tr><tr><td>Median, months (95% CI)</td><td align=\"center\">2.9 (2.6, 4.8)</td><td align=\"center\" colspan=\"2\">1.7 (1.4, 2.6)</td><td align=\"center\">2.6 (2.0, 2.8)</td><td align=\"center\">2.6 (1.7, 2.7)</td></tr><tr><td>HR(95% CI)</td><td align=\"center\" colspan=\"3\">0.52(0.35, 0.78)</td><td align=\"center\" colspan=\"2\">0.86 (0.69, 1.06)</td></tr><tr><td colspan=\"6\"><content styleCode=\"bold\">Objective response rate</content></td></tr><tr><td>Objective response rate (%)(95% CI)</td><td align=\"center\" colspan=\"2\">1.4 (0, 7.6)</td><td align=\"center\">0 (0, 4.2)</td><td align=\"center\">4.0 (1.8, 7.5)</td><td align=\"center\">5.0 (2.5, 8.7)</td></tr></tbody></table>","<table frame=\"box\" rules=\"all\"><tbody><tr><td rowspan=\"2\"/><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Leiomyosarcoma</content><content styleCode=\"bold\">Stratum</content></td></tr><tr><td align=\"center\"><content styleCode=\"bold\">Eribulin Mesylate</content><content styleCode=\"bold\"> (n=154)</content></td><td align=\"center\"><content styleCode=\"bold\">Dacarbazine  (n=149)</content></td></tr><tr><td colspan=\"3\"><content styleCode=\"bold\">Overall survival</content></td></tr><tr><td>Deaths, n (%)</td><td align=\"center\">121 (79)</td><td>116 (78)</td></tr><tr><td>Median, months (95%CI)</td><td align=\"center\">12.8 (10.3, 14.8)</td><td>12.3 (11.0, 15.1)</td></tr><tr><td>HR (95% CI)</td><td align=\"center\" colspan=\"2\">0.90 (0.69, 1.18)</td></tr><tr><td colspan=\"3\"><content styleCode=\"bold\">Progression-free survival</content></td></tr><tr><td>Events, n (%)</td><td align=\"center\">137 (89)</td><td align=\"center\">126 (85)</td></tr><tr><td>Disease progression</td><td align=\"center\">127</td><td align=\"center\">118</td></tr><tr><td>Death</td><td align=\"center\">10</td><td align=\"center\">8</td></tr><tr><td>Median, months (95% CI)</td><td align=\"center\">2.2 (1.5, 2.7)</td><td align=\"center\">2.6 (2.2, 2.9)</td></tr><tr><td>HR (95% CI)</td><td align=\"center\" colspan=\"2\">1.05 (0.81, 1.35)</td></tr><tr><td>Objective response rate (%)(95% CI)</td><td align=\"center\">5.2 (2.3, 10)</td><td align=\"center\">7.4 (3.7, 12.8)</td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with eribulin mesylate. Eribulin mesylate was not mutagenic in in vitro bacterial reverse mutation assays (Ames test). Eribulin mesylate was positive in mouse lymphoma mutagenesis assays, and was clastogenic in an in vivo rat bone marrow micronucleus assay. Fertility studies have not been conducted with eribulin mesylate in humans or animals; however, nonclinical findings in repeat-dose dog and rat toxicology studies suggest that male fertility may be compromised by treatment with eribulin mesylate. Rats exhibited testicular toxicity (hypocellularity of seminiferous epithelium with hypospermia/aspermia) following dosing with eribulin mesylate at or above 0.43 times the recommended human dose (based on body surface area) given once weekly for 3 weeks, or at or above 0.21 times the recommended human dose (based on body surface area) given once weekly for 3 out of 5 weeks, repeated for 6 cycles. Testicular toxicity was also observed in dogs given 0.64 times the recommended human dose (based on body surface area) weekly for 3 out of 5 weeks, repeated for 6 cycles."],"adverse_reactions_table":["<table frame=\"box\" rules=\"all\"><tbody align=\"center\"><tr><td><content styleCode=\"bold\">Adverse Reactions</content></td><td colspan=\"2\"><content styleCode=\"bold\">Eribulin Mesylate  </content><content styleCode=\"bold\">n=503</content></td><td colspan=\"2\"><content styleCode=\"bold\">Control </content><content styleCode=\"bold\">Group</content><content styleCode=\"bold\"> n=247</content></td></tr><tr><td/><td><content styleCode=\"bold\">All Grades</content></td><td><content styleCode=\"bold\">&#x2265; Grade 3</content></td><td><content styleCode=\"bold\">All Grades</content></td><td><content styleCode=\"bold\">&#x2265; Grade 3</content></td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Blood and lymphatic system disorders</content><sup>b</sup></td></tr><tr><td align=\"left\">Neutropenia</td><td>82%</td><td>57%</td><td>53%</td><td>23%</td></tr><tr><td align=\"left\">Anemia</td><td>58%</td><td>2%</td><td>55%</td><td>4%</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Nervous system disorders</content></td></tr><tr><td align=\"left\">Peripheral neuropathy<sup>c</sup></td><td>35%</td><td>8%</td><td>16%</td><td>2%</td></tr><tr><td align=\"left\">Headache</td><td>19%</td><td>&lt;1%</td><td>12%</td><td>&lt;1%</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">General disorders</content></td></tr><tr><td align=\"left\">Asthenia/Fatigue</td><td>54%</td><td>10%</td><td>40%</td><td>11%</td></tr><tr><td align=\"left\">Pyrexia</td><td>21%</td><td>&lt;1%</td><td>13%</td><td>&lt;1%</td></tr><tr><td align=\"left\">Mucosalinflammation</td><td>9%</td><td>1%</td><td>10%</td><td>2%</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Gastrointestinal disorders</content></td></tr><tr><td align=\"left\">Nausea</td><td>35%</td><td>1%</td><td>28%</td><td>3%</td></tr><tr><td align=\"left\">Constipation</td><td>25%</td><td>1%</td><td>21%</td><td>1%</td></tr><tr><td align=\"left\">Vomiting</td><td>18%</td><td>1%</td><td>18%</td><td>1%</td></tr><tr><td align=\"left\">Diarrhea</td><td>18%</td><td>0</td><td>18%</td><td>0</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></td></tr><tr><td align=\"left\">Arthralgia/Myalgia</td><td>22%</td><td>&lt;1%</td><td>12%</td><td>1%</td></tr><tr><td align=\"left\">Back pain</td><td>16%</td><td>1%</td><td>7%</td><td>2%</td></tr><tr><td align=\"left\">Bone pain</td><td>12%</td><td>2%</td><td>9%</td><td>2%</td></tr><tr><td align=\"left\">Pain in extremity</td><td>11%</td><td>1%</td><td>10%</td><td>1%</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Metabolism and nutrition disorders</content></td></tr><tr><td align=\"left\">Decreased weight</td><td>21%</td><td>1%</td><td>14%</td><td>&lt;1%</td></tr><tr><td align=\"left\">Anorexia</td><td>20%</td><td>1%</td><td>13%</td><td>1%</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Respiratory, thoracic, and mediastinal disorders</content></td></tr><tr><td align=\"left\">Dyspnea</td><td>16%</td><td>4%</td><td>13%</td><td>4%</td></tr><tr><td align=\"left\">Cough</td><td>14%</td><td>0</td><td>9%</td><td>0</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr><td align=\"left\">Alopecia</td><td>45%</td><td>NA<sup>d</sup></td><td>10%</td><td>NA<sup>d</sup></td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Infections</content></td></tr><tr><td align=\"left\">Urinary Tract Infection</td><td>10%</td><td>1%</td><td>5%</td><td>0</td></tr><tr align=\"left\"><td colspan=\"5\"><sup>a.</sup> adverse reactions were graded per National Cancer Institute Criteria for Adverse Events version 4.0. <sup>b</sup> based upon laboratory data <sup>c</sup> includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motorneuropathy, polyneuropathy, peripheral sensory neuropathy, and paraesthesia. <sup>d</sup> not applicable; (grading system does not specify &gt; Grade 2 for alopecia).</td></tr></tbody></table>","<table frame=\"box\" rules=\"all\"><tbody align=\"center\"><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\"> Table 3: Adverse Reactions<sup>a</sup> Occurring in &#x2265;10% (all Grades) of Patients Treated on the</content><content styleCode=\"bold\">Eribulin Mesylate arm and at a Higher Incidence than in the Dacarbazine Arm (Between Arm Difference of &#x2265;5% for All Grades or &#x2265;2% for Grades 3 and 4) (Study 2)<sup>b</sup></content></td></tr><tr><td rowspan=\"2\"><content styleCode=\"bold\">Adverse Reaction</content></td><td colspan=\"2\"><content styleCode=\"bold\">Eribulin Mesylate</content><content styleCode=\"bold\"> n=223</content></td><td colspan=\"2\"><content styleCode=\"bold\">Dacarbazine</content> <content styleCode=\"bold\">n=221</content></td></tr><tr><td><content styleCode=\"bold\">All Grades</content></td><td><content styleCode=\"bold\">Grades 3 to 4</content></td><td><content styleCode=\"bold\">All Grades</content></td><td><content styleCode=\"bold\">Grades 3 to 4</content></td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Nervous system disorders</content></td></tr><tr><td align=\"left\">Peripheral Neuropathy<sup>c</sup></td><td>29%</td><td>3.1%</td><td>8%</td><td>0.5%</td></tr><tr><td align=\"left\">Headache</td><td>18%</td><td>0%</td><td>10%</td><td>0%</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">General disorders</content></td></tr><tr><td align=\"left\">Pyrexia</td><td>28%</td><td>0.9%</td><td>14%</td><td>0.5%</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Gastrointestinal disorders</content></td></tr><tr><td align=\"left\">Constipation</td><td>32%</td><td>0.9%</td><td>26%</td><td>0.5%</td></tr><tr><td align=\"left\">Abdominal pain<sup>d</sup></td><td>29%</td><td>1.8%</td><td>23%</td><td>4.1%</td></tr><tr><td align=\"left\">Stomatitis</td><td>14%</td><td>0.9%</td><td>5%</td><td>0.5%</td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr><td align=\"left\">Alopecia</td><td>35%</td><td>NA<sup>e</sup></td><td>2.7%</td><td>NA<sup>e</sup></td></tr><tr><td align=\"left\" colspan=\"5\"><content styleCode=\"bold\">Infections</content></td></tr><tr><td align=\"left\">Urinary tract infection</td><td>11%</td><td>2.2%</td><td>5%</td><td>0.5%</td></tr><tr><td align=\"left\" colspan=\"5\"><sup>a</sup> Adverse reactions were graded per National Cancer Institute Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03). <sup>b</sup> Safety data from one study site enrolling six patients were excluded. <sup>c</sup> Includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensory neuropathy, and paraesthesia. <sup>d</sup> Includes abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort. <sup>e</sup> Not applicable; (grading system does not specify &gt; Grade 2 for alopecia).</td></tr></tbody></table>","<table frame=\"box\" rules=\"all\"><tbody><tr><td colspan=\"5\"><content styleCode=\"bold\">Table 4: Laboratory Abnormalities Occurring in &#x2265;10% (all Grades) of Patients Treated on the Eribulin Mesylate arm and at a Higher Incidence than in the Dacarbazine Arm (Between Arm Difference of &#x2265;5% for All Grades or &#x2265;2% for Grades 3 and 4)<sup>a</sup> (Study 2)<sup>&#x2020;</sup></content></td></tr><tr><td rowspan=\"2\"><content styleCode=\"bold\">Laboratory Abnormality</content></td><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Eribulin Mesylate </content></td><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Dacarbazine</content></td></tr><tr><td align=\"center\"><content styleCode=\"bold\">All Grades</content></td><td align=\"center\"><content styleCode=\"bold\">Grades 3 to 4</content></td><td align=\"center\"><content styleCode=\"bold\">All Grades</content></td><td align=\"center\"><content styleCode=\"bold\">Grades 3 to 4</content></td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Hematology</content></td></tr><tr><td>Anemia</td><td align=\"center\">70%</td><td align=\"center\">4.1%</td><td align=\"center\">52%</td><td align=\"center\">6%</td></tr><tr><td>Neutropenia</td><td align=\"center\">63%</td><td align=\"center\">32%</td><td align=\"center\">30%</td><td align=\"center\">8.9%</td></tr><tr><td colspan=\"5\"><content styleCode=\"bold\">Chemistry</content></td></tr><tr><td>Increased alanine aminotransferase (ALT)</td><td align=\"center\">43%</td><td align=\"center\">2.3%</td><td align=\"center\">28%</td><td align=\"center\">2.3%</td></tr><tr><td>Increased aspartate aminotransferase (AST)</td><td align=\"center\">36%</td><td align=\"center\">0.9%</td><td align=\"center\">16%</td><td align=\"center\">0.5%</td></tr><tr><td>Hypokalemia</td><td align=\"center\">30%</td><td align=\"center\">5.4%</td><td align=\"center\">14%</td><td align=\"center\">2.8%</td></tr><tr><td>Hypocalcemia</td><td align=\"center\">28%</td><td align=\"center\">5%</td><td align=\"center\">18%</td><td align=\"center\">1.4%</td></tr><tr><td>Hypophosphatemia</td><td align=\"center\">20%</td><td align=\"center\">3.2%</td><td align=\"center\">11%</td><td align=\"center\">1.4%</td></tr><tr><td colspan=\"5\"><sup>a</sup> Each test incidence is based on the number of patients who had both baseline and at least one on-study measurement and at least 1 grade increase from baseline. Eribulin mesylate group (range221 to 222) and dacarbazine group (range 214 to 215). <content styleCode=\"bold\"><sup>&#x2020;</sup></content>Laboratory results were graded per NCI CTCAE v4.03.</td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Neutropenia Advise patients to contact their health care provider for a fever of 100.5°F or greater or other signs or symptoms of infection such as chills, cough, or burning or pain on urination [see Warnings and Precautions ( 5.1) ]. Peripheral Neuropathy Advise patients to inform their healthcare providers of new or worsening numbness, tingling and pain in their extremities [see Warnings and Precautions ( 5.2 ) ] . Embryo-Fetal Toxicity Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.1 )]. Advise females of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for at least 2 weeks after the final dose [see Use in Specific Populations ( 8.3 )]. Advise males with female partners of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for 3.5 months following the final dose [see Use in Specific Populations ( 8.3 )] . Lactation Advise women not to breastfeed during treatment with eribulin mesylate injection and for 2 weeks after the final dose [see Use in Specific Populations ( 8.2 ) ]. Rx Only Distributed by: Dr.Reddy's Laboratories Inc., Princeton, NJ 08540 Made in India Issued: 03/2023"],"spl_unclassified_section":["15 REFERENCES 1. OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Administer 1.4 mg/m 2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. ( 2.1 ) Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. ( 2.1 ) Do not mix with other drugs or administer with dextrose-containing solutions. ( 2.3 ) 2.1 Recommended Dose The recommended dose of eribulin mesylate injection is 1.4 mg/m 2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. The recommended dose of eribulin mesylate injection in patients with mild hepatic impairment (Child-Pugh A) is 1.1 mg/m 2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle [see Use in Specific Populations ( 8.6 )] . The recommended dose of eribulin mesylate injection in patients with moderate hepatic impairment (Child-Pugh B) is 0.7 mg/m 2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle [see Use in Specific Populations ( 8.6 )] . The recommended dose of eribulin mesylate injection in patients with moderate or severe renal impairment (creatinine clearance (CLcr) 15 to 49 mL/min) is 1.1 mg/m 2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle [see Use in Specific Populations ( 8.7 )]. 2.2 Dose Modification Assess for peripheral neuropathy and obtain complete blood cell counts prior to each dose. Recommended dose delays • Do not administer eribulin mesylate injection on Day 1 or Day 8 for any of the following: - ANC < 1,000/mm 3 - Platelets < 75,000/mm 3 - Grade 3 or 4 non-hematological toxicities. • The Day 8 dose may be delayed for a maximum of 1 week. - If toxicities do not resolve or improve to ≤ Grade 2 severity by Day 15, omit the dose. - If toxicities resolve or improve to ≤ Grade 2 severity by Day 15, administer eribulin mesylate injection at a reduced dose and initiate the next cycle no sooner than 2 weeks later. Recommended dose reductions • If a dose has been delayed for toxicity and toxicities have recovered to Grade 2 severity or less, resume eribulin mesylate injection at a reduced dose as set out in Table 1. • Do not re-escalate eribulin mesylate injection dose after it has been reduced. Table 1: Recommended Dose Reductions Event Description Recommended Eribulin Mesylate Injection Dose Permanently reduce the 1.4 mg/m 2 eribulin mesylate injection dose for any of the following: 1.1 mg/m 2 ANC <500/mm 3 for >7 days ANC <1,000 /mm 3 with fever or infection Platelets <25,000/mm 3 Platelets <50,000/mm 3 requiring transfusion Non-hematologic Grade 3 or 4 toxicities Omission or delay of Day 8 eribulin mesylate injection dose in previous cycle for toxicity Occurrence of any event requiring permanent dose reduction while receiving 1.1 mg/m 2 0.7 mg/m 2 Occurrence of any event requiring permanent dose reduction while receiving 0.7 mg/m 2 Discontinue eribulin mesylate injection ANC = absolute neutrophil count. Toxicities graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. 2.3 Instructions for Preparation and Administration Aseptically withdraw the required amount of eribulin mesylate injection from the single-dose vial and administer undiluted or diluted in 100 mL of 0.9% Sodium Chloride Injection, USP. Do not dilute in or administer through an intravenous line containing solutions with dextrose. Do not administer in the same intravenous line concurrent with the other medicinal products. Store undiluted eribulin mesylate injection in the syringe for up to 4 hours at room temperature or for up to 24 hours under refrigeration at 4°C (40°F). Store diluted solutions of eribulin mesylate injection for up to 4 hours at room temperature or up to 24 hours under refrigeration at 4°C (40°F). Discard unused portions of the vial."],"spl_product_data_elements":["Eribulin Mesylate Eribulin Mesylate ERIBULIN MESYLATE ERIBULIN ALCOHOL WATER SODIUM HYDROXIDE HYDROCHLORIC ACID structure figure1 figure2 viallabel cartonlabel"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 1 mg/2 mL (0.5 mg/mL) eribulin mesylate is a clear, colorless, sterile solution in a single-dose vial. Injection: 1 mg per 2 mL (0.5 mg per mL) eribulin mesylate in a single-dose vial ( 3 )"],"spl_patient_package_insert":["PATIENT INFORMATION Eribulin Mesylate (er'' i bue' lin mes' i late) Injection for intravenous use What is the most important information I should know about eribulin mesylate injection? Eribulin mesylate injection can cause serious side effects, including: • Low white blood cell count (neutropenia) . This can lead to serious infections that could lead to death. Your healthcare provider will check your blood cell counts before you receive each dose of eribulin mesylate injection and during treatment. Call your healthcare provider right away if you develop any of these symptoms of infection: fever (temperature above 100.5°F) cough chills burning or pain when you urinate • N umbness, tingling, or pain in your hands or feet (peripheral neuropathy) . Peripheral neuropathy is common with eribulin mesylate injection and sometimes can be severe. Tell your healthcare provider if you have new or worsening symptoms of peripheral neuropathy. • Your healthcare provider may delay, decrease your dose, or stop treatment with eribulin mesylate injection if you have side effects. See “ What are possible side effects of eribulin mesylate injection?” for more information about side effects. What is eribulin mesylate injection? Eribulin mesylate injection is a prescription medicine used to treat people with: • Breast cancer that has spread to other parts of the body, and who have already received certain types of anticancer medicines after the cancer has spread • Liposarcoma that cannot be treated with surgery or has spread to other parts of the body, and who have received treatment with a certain type of anticancer medicine It is not known if eribulin mesylate injection is safe and effective in children under 18 years of age. Before you receive eribulin mesylate injection, tell your healthcare provider about all of your medical conditions, including if you: • have liver or kidney problems • have heart problems, including a problem called congenital long QT syndrome • have low potassium or low magnesium in your blood • are pregnant or plan to become pregnant. Eribulin mesylate injection can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with eribulin mesylate injection. Females who are able to become pregnant should use an effective birth control during treatment with eribulin mesylate injection and for at least 2 weeks after the final dose of eribulin mesylate injection. Males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with eribulin mesylate injection and for 3 1/2 months (14 weeks) after the final dose of eribulin mesylate injection. • are breastfeeding or plan to breast feed. It is not known if eribulin mesylate passes into your breast milk. Do not breastfeed during treatment with eribulin mesylate injection and for 2 weeks after the final dose of eribulin mesylate injection. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive eribulin mesylate injection? • Eribulin mesylate injection is given by intravenous (IV) injection in your vein. • Eribulin mesylate injection is given in “cycles” of treatment, with each cycle lasting 21 days. • Eribulin mesylate injection is usually given on day 1 and day 8 of a treatment cycle. What are the possible side effects of eribulin mesylate injection ? Eribulin mesylate injection may cause serious side effects, including: • See “ What is the most important information I should know about eribulin mesylate injection?” • Eribulin mesylate injection can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with eribulin mesylate injection to check for heart problems. The most common side effects of eribulin mesylate injection in people with breast cancer include: • low white blood cell count (neutropenia) • nausea • low red blood cell count (anemia) • constipation • weakness or tiredness • hair loss (alopecia) The most common side effects of eribulin mesylate injection in people with liposarcoma include: • tiredness • stomach pain • nausea • fever • hair loss (alopecia) • constipation Your healthcare provider will do blood tests before and during treatment while you are taking eribulin mesylate injection. The most common changes to blood tests in people with liposarcoma include: • low white blood cell count (neutropenia) • decreased blood levels of potassium or calcium Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of eribulin mesylate injection. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about eribulin mesylate injection Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or health care provider for information about eribulin mesylate injection that is written for health professionals. What are the ingredients in eribulin mesylate injection? Active Ingredient : eribulin mesylate Inactive Ingredients: dehydrated alcohol, water for injection, and sodium hydroxide or hydrochloric acid may be used for pH adjustment. Rx Only Distributed by: Dr. Reddy’s Laboratories Inc., Princenton NJ, 08540 Made in India For more information, call 1-888-375-3784. This Patient Information has been approved by the U.S. Food and Drug Administration. To reorder additional Patient Information Sheets, contact Dr. Reddy’s Customer Service at 1‑866‑733-3952. Issued: 03/2023"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Do not breastfeed. ( 8.2 ) Hepatic Impairment: A lower starting dose is recommended for patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment. Patients with severe hepatic impairment (Child-Pugh C) were not studied. ( 8.6 ) Renal Impairment: A lower starting dose is recommended for patients with moderate (CLcr 30 to 49 mL/min) or severe (CLcr 15 to 29 mL/min) renal impairment. ( 8.7 ) 8.1 Pregnancy Risk Summary Based on findings from an animal reproduction study and its mechanism of action, eribulin mesylate, can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )]. There are no available data on the use of eribulin mesylate during pregnancy. In an animal reproduction study, eribulin mesylate caused embryo-fetal toxicity when administered to pregnant rats during organogenesis at doses below the recommended human dose [see Data] . Advise pregnant women of the potential risk to a fetus. The estimated background risks of major birth defects and miscarriage for the indicated populations are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In an embryo-fetal developmental toxicity study, pregnant rats received intravenous infusion of eribulin mesylate during organogenesis (Gestation Days 8, 10, and 12) at doses approximately 0.04, 0.13, 0.43 and 0.64 times the recommended human dose, based on body surface area. Increased abortion and severe fetal external or soft tissue malformations, including the absence of a lower jaw and tongue, or stomach and spleen, were observed at doses 0.64 times the recommended human dose of 1.4 mg/m 2 based on body surface area. Increased embryo-fetal death/resorption, reduced fetal weights, and minor skeletal anomalies consistent with developmental delay were also reported at doses at or above a maternally toxic dose of approximately 0.43 times the recommended human dose. 8.2 Lactation Risk Summary There is no information regarding the presence of eribulin mesylate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. No lactation studies in animals were conducted. Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with eribulin mesylate injection and for 2 weeks after the final dose. 8.3 Females and Males of Reproductive Potential Contraception Females Based on findings from an animal reproduction study and its mechanism of action, eribulin mesylate can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for at least 2 weeks following the final dose . Males Based on its mechanism of action, advise males with female partners of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for 3.5 months following the final dose. Infertility Males Based on animal data, eribulin mesylate may result in damage to male reproductive tissues leading to impaired fertility of unknown duration [see Nonclinical Toxicology ( 13.1 )]. 8.4 Pediatric Use The safety and effectiveness of eribulin mesylate injection in pediatric patients have not been established. Pediatric use information describing clinical studies in which efficacy was not demonstrated is approved for Eisai Inc’s HALAVEN ® (eribulin mesylate) injection. However, due to Eisai Inc’s marketing exclusivity rights, this drug product is not labeled with that information. 8.5 Geriatric Use Study 1 did not include sufficient numbers of subjects with metastatic breast cancer aged 65 years and older to determine whether they respond differently from younger subjects. Of the 827 subjects who received the recommended dose and schedule of eribulin mesylate in clinical studies with advanced breast cancer, 15% (121/827) were 65 and older and 2% (17/827) patients were 75 and older. No overall differences in safety were observed between these subjects and younger subjects. Clinical studies of eribulin mesylate did not include a sufficient number of subjects in Study 2 aged 65 years and older to determine whether they respond differently from younger subjects. 8.6 Hepatic Impairment Administration of eribulin mesylate at a dose of 1.1 mg/m 2 to patients with mild hepatic impairment and 0.7 mg/m 2 to patients with moderate hepatic impairment resulted in similar exposure to eribulin as a dose of 1.4 mg/m 2 to patients with normal hepatic function. Therefore, a lower starting dose of 1.1 mg/m 2 is recommended for patients with mild hepatic impairment (Child-Pugh A) and of 0.7 mg/m 2 is recommended for patients with moderate hepatic impairment (Child-Pugh B). Eribulin mesylate was not studied in patients with severe hepatic impairment (Child-Pugh C) [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.3 )]. 8.7 Renal Impairment For patients with moderate or severe renal impairment (CLcr 15 to 49 mL/min), reduce the starting dose to 1.1 mg/m 2 [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.3 )]."],"dosage_and_administration_table":["<table frame=\"box\" rules=\"all\"><tbody><tr><td><content styleCode=\"bold\">Event Description</content></td><td><content styleCode=\"bold\">Recommended Eribulin Mesylate Injection Dose</content></td></tr><tr><td><content styleCode=\"bold\">Permanently reduce the 1.4 mg/m<sup>2</sup> eribulin mesylate injection dose for any of the</content><content styleCode=\"bold\">following:</content></td><td align=\"center\" rowspan=\"7\"> 1.1 mg/m<sup>2</sup></td></tr><tr><td>ANC &lt;500/mm<sup>3</sup> for &gt;7 days</td></tr><tr><td>ANC &lt;1,000 /mm<sup>3</sup> with fever or infection</td></tr><tr><td>Platelets &lt;25,000/mm<sup>3</sup></td></tr><tr><td>Platelets &lt;50,000/mm<sup>3</sup> requiring transfusion</td></tr><tr><td>Non-hematologic Grade 3 or 4 toxicities</td></tr><tr><td>Omission or delay of Day 8 eribulin mesylate injection dose in previous cycle for toxicity</td></tr><tr><td><content styleCode=\"bold\">Occurrence </content> of any event requiring permanent dose reduction while receiving 1.1 mg/m<sup>2</sup></td><td align=\"center\"> 0.7 mg/m<sup>2</sup></td></tr><tr><td><content styleCode=\"bold\">Occurrence </content>of any event requiring permanent dose reduction while receiving 0.7 mg/m<sup>2</sup></td><td align=\"center\"> Discontinue eribulin mesylate injection</td></tr><tr><td colspan=\"2\">ANC = absolute neutrophil count.  Toxicities graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.</td></tr></tbody></table>"],"spl_patient_package_insert_table":["<table frame=\"box\" rules=\"all\"><tbody><tr><td align=\"center\"><content styleCode=\"bold\">PATIENT INFORMATION</content><content styleCode=\"bold\"> Eribulin Mesylate </content><content styleCode=\"bold\">(er&apos;&apos; i bue&apos; lin mes&apos; i late)</content> <content styleCode=\"bold\">Injection</content> for intravenous use</td></tr><tr><td><content styleCode=\"bold\">What is the most important information I should know about eribulin mesylate injection?  Eribulin mesylate injection can cause serious side effects, including:  </content><content styleCode=\"bold\">&#x2022; Low white blood cell count (neutropenia)</content>. This can lead to serious infections that could lead to death. Your healthcare provider will check your blood cell counts before you receive each dose of eribulin mesylate injection and during treatment. Call your healthcare provider right away if you develop any of these symptoms of infection:<list><item>fever (temperature above 100.5&#xB0;F) </item><item>cough</item><item>chills </item><item>burning or pain when you urinate</item></list>&#x2022; N<content styleCode=\"bold\">umbness, tingling, or pain in your hands or feet (peripheral neuropathy)</content>. Peripheral neuropathy is common with eribulin mesylate injection and sometimes can be severe. Tell your healthcare provider if you have new or worsening symptoms of peripheral neuropathy. &#x2022; Your healthcare provider may delay, decrease your dose, or stop treatment with eribulin mesylate injection if you have side effects.  See &#x201C;<content styleCode=\"bold\">What are possible side effects of eribulin mesylate injection?&#x201D; </content>for more information about side effects.</td></tr><tr><td><content styleCode=\"bold\">What is eribulin mesylate injection? Eribulin mesylate injection is a prescription medicine used to treat people with:</content> &#x2022; Breast cancer<list><item>that has spread to other parts of the body, <content styleCode=\"bold\">and</content></item><item>who have already received certain types of anticancer medicines after the cancer has spread</item></list>&#x2022; Liposarcoma<list><item> that cannot be treated with surgery or has spread to other parts of the body, <content styleCode=\"bold\">and</content></item><item>who have received treatment with a certain type of anticancer medicine</item></list>It is not known if eribulin mesylate injection is safe and effective in children under 18 years of age.</td></tr><tr><td><content styleCode=\"bold\">Before you receive eribulin mesylate injection, tell your healthcare provider about all of your medical conditions, including if you: </content>&#x2022; have liver or kidney problems &#x2022; have heart problems, including a problem called congenital long QT syndrome &#x2022; have low potassium or low magnesium in your blood &#x2022; are pregnant or plan to become pregnant. Eribulin mesylate injection can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with eribulin mesylate injection.<content styleCode=\"bold\"/><list><item><content styleCode=\"bold\">Females </content>who are able to become pregnant should use an effective birth control during treatment with eribulin mesylate injection and for at least 2 weeks after the final dose of eribulin mesylate injection.</item><item><content styleCode=\"bold\">Males </content>should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with eribulin mesylate injection and for 3 1/2 months (14 weeks) after the final dose of eribulin mesylate injection.</item></list>&#x2022; are breastfeeding or plan to breast feed. It is not known if eribulin mesylate passes into your breast milk. Do not breastfeed during treatment with eribulin mesylate injection and for 2 weeks after the final dose of eribulin mesylate injection. <content styleCode=\"bold\"> Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td></tr><tr><td><content styleCode=\"bold\">How will I receive eribulin mesylate injection?</content> &#x2022; Eribulin mesylate injection is given by intravenous (IV) injection in your vein. &#x2022; Eribulin mesylate injection is given in &#x201C;cycles&#x201D; of treatment, with each cycle lasting 21 days. &#x2022; Eribulin mesylate injection is usually given on day 1 and day 8 of a treatment cycle.</td></tr><tr><td><content styleCode=\"bold\">What are the possible side effects of</content><content styleCode=\"bold\"> eribulin mesylate injection</content><content styleCode=\"bold\">?</content> Eribulin mesylate injection may cause serious side effects, including: &#x2022; See &#x201C;<content styleCode=\"bold\">What is the most important information I should know about eribulin mesylate injection?&#x201D;</content> <content styleCode=\"bold\">&#x2022; Eribulin mesylate injection can cause changes in your heartbeat (called QT prolongation). </content>This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with eribulin mesylate injection to check for heart problems.  The most common side effects of eribulin mesylate injection in people with breast cancer include: &#x2022; low white blood cell count (neutropenia) &#x2022; nausea &#x2022; low red blood cell count (anemia) &#x2022; constipation &#x2022; weakness or tiredness &#x2022; hair loss (alopecia)   The most common side effects of eribulin mesylate injection in people with liposarcoma include: &#x2022; tiredness &#x2022; stomach pain &#x2022; nausea &#x2022; fever &#x2022; hair loss (alopecia) &#x2022; constipation   Your healthcare provider will do blood tests before and during treatment while you are taking eribulin mesylate injection. The most common changes to blood tests in people with liposarcoma include: &#x2022; low white blood cell count (neutropenia) &#x2022; decreased blood levels of potassium or calcium   Tell your healthcare provider about any side effect that bothers you or that does not go away.  These are not all the possible side effects of eribulin mesylate injection. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </td></tr><tr><td><content styleCode=\"bold\">General information about eribulin mesylate injection</content>  Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or health care provider for information about eribulin mesylate injection that is written for health professionals.</td></tr><tr><td><content styleCode=\"bold\">What are the ingredients in eribulin mesylate injection? </content><content styleCode=\"bold\">Active Ingredient</content>: eribulin mesylate <content styleCode=\"bold\"> Inactive Ingredients: </content>dehydrated alcohol, water for injection, and sodium hydroxide or hydrochloric acid may be used for pH adjustment.   Rx Only   Distributed by: <content styleCode=\"bold\"> Dr. Reddy&#x2019;s Laboratories Inc.,</content>  Princenton NJ, 08540 <content styleCode=\"bold\"> Made in India</content>   For more information, call 1-888-375-3784.</td></tr></tbody></table>"],"package_label_principal_display_panel":["PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION Eribulin Mesylate Injection , 1 mg/2 mL (0.5 mg/mL) - Vial Label","Eribulin Mesylate Injection , 1 mg/2 mL (0.5 mg/mL) - Carton Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with eribulin mesylate. Eribulin mesylate was not mutagenic in in vitro bacterial reverse mutation assays (Ames test). Eribulin mesylate was positive in mouse lymphoma mutagenesis assays, and was clastogenic in an in vivo rat bone marrow micronucleus assay. Fertility studies have not been conducted with eribulin mesylate in humans or animals; however, nonclinical findings in repeat-dose dog and rat toxicology studies suggest that male fertility may be compromised by treatment with eribulin mesylate. Rats exhibited testicular toxicity (hypocellularity of seminiferous epithelium with hypospermia/aspermia) following dosing with eribulin mesylate at or above 0.43 times the recommended human dose (based on body surface area) given once weekly for 3 weeks, or at or above 0.21 times the recommended human dose (based on body surface area) given once weekly for 3 out of 5 weeks, repeated for 6 cycles. Testicular toxicity was also observed in dogs given 0.64 times the recommended human dose (based on body surface area) weekly for 3 out of 5 weeks, repeated for 6 cycles."]},"tags":[{"label":"Microtubule Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Tubulin beta","category":"target"},{"label":"TUBB","category":"gene"},{"label":"TUBB1","category":"gene"},{"label":"TUBB2A","category":"gene"},{"label":"L01XX41","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"LOE Approaching","category":"status"},{"label":"Liposarcoma","category":"indication"},{"label":"Metastatic Breast Carcinoma","category":"indication"},{"label":"Eisai Inc","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":1386.767,"date":"","count":731,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 731 times (LLR=1387)"},{"llr":1290.988,"date":"","count":554,"signal":"Malignant neoplasm progression","source":"DrugCentral FAERS","actionTaken":"Reported 554 times (LLR=1291)"},{"llr":834.497,"date":"","count":476,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 476 times (LLR=834)"},{"llr":420.08,"date":"","count":278,"signal":"Neuropathy peripheral","source":"DrugCentral FAERS","actionTaken":"Reported 278 times (LLR=420)"},{"llr":406.065,"date":"","count":158,"signal":"Metastases to liver","source":"DrugCentral FAERS","actionTaken":"Reported 158 times (LLR=406)"},{"llr":392.424,"date":"","count":149,"signal":"Metastases to bone","source":"DrugCentral FAERS","actionTaken":"Reported 149 times (LLR=392)"},{"llr":360.58,"date":"","count":153,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 153 times (LLR=361)"},{"llr":349.177,"date":"","count":220,"signal":"Leukopenia","source":"DrugCentral FAERS","actionTaken":"Reported 220 times (LLR=349)"},{"llr":260.225,"date":"","count":175,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 175 times (LLR=260)"},{"llr":211.395,"date":"","count":143,"signal":"Neutrophil count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 143 times (LLR=211)"},{"llr":201.223,"date":"","count":40,"signal":"Pseudocirrhosis","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=201)"},{"llr":181.986,"date":"","count":65,"signal":"Breast cancer metastatic","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=182)"},{"llr":160.952,"date":"","count":175,"signal":"Disease progression","source":"DrugCentral FAERS","actionTaken":"Reported 175 times (LLR=161)"},{"llr":153.465,"date":"","count":111,"signal":"Mucosal inflammation","source":"DrugCentral FAERS","actionTaken":"Reported 111 times (LLR=153)"},{"llr":152.018,"date":"","count":83,"signal":"Palmar-plantar erythrodysaesthesia syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 83 times (LLR=152)"}],"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"}],"commonSideEffects":[{"effect":"Neutropenia","drugRate":"57%","severity":"serious","_validated":true},{"effect":"Anemia","drugRate":"2%","severity":"common","_validated":true},{"effect":"Asthenia/Fatigue","drugRate":"10%","severity":"common","_validated":true},{"effect":"Peripheral neuropathy","drugRate":"8%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"1%","severity":"common","_validated":true},{"effect":"Constipation","drugRate":"1%","severity":"common","_validated":true},{"effect":"Pyrexia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"Headache","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"Mucosal inflammation","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Vomiting","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Diarrhea","drugRate":"0%","severity":"mild","_validated":true},{"effect":"Arthralgia/Myalgia","drugRate":"<1%","severity":"mild","_validated":true},{"effect":"Back pain","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Bone pain","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Pain in extremity","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Decreased weight","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Anorexia","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Dyspnea","drugRate":"4%","severity":"common","_validated":true},{"effect":"Cough","drugRate":"0%","severity":"mild","_validated":true},{"effect":"Alopecia","drugRate":"NAd","severity":"unknown"},{"effect":"Urinary Tract Infection","drugRate":"1%","severity":"mild","_validated":true},{"effect":"Eye Disorders: increased lacrimation","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal Disorders: dyspepsia","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal Disorders: abdominal pain","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal Disorders: stomatitis","drugRate":"reported","severity":"unknown"},{"effect":"General Disorders and Administration Site Conditions: peripheral edema","drugRate":"reported","severity":"unknown"},{"effect":"Infections and Infestations: upper respiratory tract infection","drugRate":"reported","severity":"unknown"},{"effect":"Metabolism and Nutrition Disorders: hypokalemia","drugRate":"reported","severity":"unknown"}],"contraindications":["Bradycardia","Chronic heart failure","Congenital long QT syndrome","Constipation","Hypokalemia","Hypomagnesemia","Neutropenic disorder","Peripheral nerve disease","Pregnancy, function","Prolonged QT interval","Thrombocytopenic disorder"],"specialPopulations":{"Pregnancy":"HALAVEN can cause fetal harm when administered to pregnant woman. There are no available data on the use of HALAVEN during pregnancy. In an animal reproduction study, eribulin mesylate caused embryo-fetal toxicity when administered to pregnant rats during organogenesis at doses below the recommended human dose. Advise pregnant women of the potential risk to fetus.","Geriatric use":"Study did not include sufficient numbers of subjects with metastatic breast cancer aged 65 years and older to determine whether they respond differently from younger subjects. Of the 827 subjects who received the recommended dose and schedule of HALAVEN in clinical studies with advanced breast cancer, 15% (121/827) were 65 and older, and 2% (17/827) patients were 75 and older. No overall differences in safety were observed between these subjects and younger subjects.","Paediatric use":"The safety and effectiveness of HALAVEN in pediatric patients below the age of 18 years have not been established.","Renal impairment":"lower starting dose is recommended for patients with moderate (CLcr 30-49 mL/min) or severe (CLcr 15-29 mL/min) renal impairment.","Hepatic impairment":"lower starting dose is recommended for patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment. Patients with severe hepatic impairment (Child-Pugh C) were not studied."}},"trials":[],"aliases":[],"company":"Eisai","patents":[{"applNo":"N201532","source":"FDA Orange Book","status":"Active","expires":"Jan 8, 2027","useCode":"","territory":"US","drugProduct":true,"patentNumber":"RE46965","drugSubstance":false},{"applNo":"N201532","source":"FDA Orange Book","status":"Active","expires":"Jul 8, 2027","useCode":"","territory":"US","drugProduct":false,"patentNumber":"RE46965*PED","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ERIBULIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:05:52.527973+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T02:05:52.527888+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Eribulin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T02:06:00.554684+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:05:58.840804+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T02:05:52.600341+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:05:59.195679+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:05:51.267600+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:05:51.267629+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1683590/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:06:00.087597+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA217473","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:05:51.267633+00:00"}},"allNames":"halaven","offLabel":[],"synonyms":["eribulin mesylate","eribulin","halaven","E7389","eribulin mesilate"],"timeline":[{"date":"2010-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from EISAI INC to Eisai Inc"},{"date":"2010-11-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Eisai Inc)"},{"date":"2011-03-17","type":"positive","source":"DrugCentral","milestone":"EMA approval"},{"date":"2024-04-05","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"},{"date":"2025-09-13","type":"negative","source":"FDA Orange Book","milestone":"M-280 exclusivity expires"},{"date":"2026-03-13","type":"negative","source":"FDA Orange Book","milestone":"Pediatric exclusivity expires"}],"approvals":[{"date":"2010-11-15","orphan":false,"company":"EISAI INC","regulator":"FDA"},{"date":"2011-03-17","orphan":false,"company":"","regulator":"EMA"}],"brandName":"Halaven","ecosystem":[{"indication":"Liposarcoma","otherDrugs":[{"name":"trabectedin","slug":"trabectedin","company":"Janssen Prods"}],"globalPrevalence":null},{"indication":"Metastatic Breast Carcinoma","otherDrugs":[{"name":"capecitabine","slug":"capecitabine","company":"Hoffmann La Roche"},{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"estradiol","slug":"estradiol","company":"Bristol Myers Squibb"}],"globalPrevalence":null}],"mechanism":{"target":"Tubulin beta","novelty":"Follow-on","targets":[{"gene":"TUBB","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta chain"},{"gene":"TUBB1","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-1 chain"},{"gene":"TUBB2A","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-2A chain"},{"gene":"TUBB2B","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-2B chain"},{"gene":"TUBB3","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-3 chain"},{"gene":"TUBB4A","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-4A chain"},{"gene":"TUBB4B","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-4B chain"},{"gene":"TUBB6","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-6 chain"},{"gene":"TUBB8","source":"DrugCentral","target":"Tubulin beta","protein":"Tubulin beta-8 chain"}],"modality":"Small Molecule","drugClass":"Microtubule Inhibitor","explanation":"Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage.In addition, eribulin treatment of human breast cancer cells caused changes in morphology and gene expression as well as decreased migration and invasiveness in vitro. In mouse xenograft models of human breast cancer, eribulin treatment was associated with increased vascular perfusion and permeability in the tumor cores, resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with change in phenotype.","oneSentence":"Halaven works by binding to tubulin beta, disrupting microtubule dynamics and leading to cell death.","technicalDetail":"Halaven (ERIBULIN) binds to tubulin beta, a subunit of microtubules, and inhibits microtubule polymerization and dynamics, leading to cell cycle arrest at the G2/M phase and apoptosis through the activation of caspases."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Eribulin","title":"Eribulin","extract":"Eribulin, sold under the brand name Halaven among others, is an anti-cancer medication used to treat breast cancer and liposarcoma."},"commercial":{"launchDate":"2010","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2010-11-15, EISAI INC)","annualRevenue":400,"revenueSource":"Verified: Eisai AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4171","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ERIBULIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ERIBULIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Eribulin","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:06:24.501360","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:06:03.887266+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"asparaginase","drugSlug":"asparaginase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"altretamine","drugSlug":"altretamine","fdaApproval":"1990-12-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"hydroxycarbamide","drugSlug":"hydroxycarbamide","fdaApproval":"1967-12-07","relationship":"same-class"},{"drugName":"pentostatin","drugSlug":"pentostatin","fdaApproval":"1991-10-11","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"masoprocol","drugSlug":"masoprocol","fdaApproval":"1992-09-04","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"mitotane","drugSlug":"mitotane","fdaApproval":"1970-07-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"pegaspargase","drugSlug":"pegaspargase","fdaApproval":"1994-02-01","relationship":"same-class"},{"drugName":"arsenic trioxide","drugSlug":"arsenic-trioxide","fdaApproval":"2000-09-25","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"denileukin diftitox","drugSlug":"denileukin-diftitox","fdaApproval":"1999-02-05","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"anagrelide","drugSlug":"anagrelide","fdaApproval":"1997-03-14","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"omacetaxine mepesuccinate","drugSlug":"omacetaxine-mepesuccinate","fdaApproval":"2012-10-26","patentExpiry":"Oct 26, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"aflibercept","drugSlug":"aflibercept","fdaApproval":"2011-11-18","relationship":"same-class"},{"drugName":"venetoclax","drugSlug":"venetoclax","fdaApproval":"2016-04-11","patentExpiry":"Sep 6, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"enasidenib","drugSlug":"enasidenib","fdaApproval":"2017-08-01","patentExpiry":"Sep 16, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivosidenib","drugSlug":"ivosidenib","fdaApproval":"2018-07-20","patentExpiry":"Oct 18, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selinexor","drugSlug":"selinexor","fdaApproval":"2019-07-03","patentExpiry":"Jul 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tagraxofusp","drugSlug":"tagraxofusp","fdaApproval":"2018-12-21","relationship":"same-class"},{"drugName":"lurbinectedin","drugSlug":"lurbinectedin","fdaApproval":"2020-06-15","patentExpiry":"May 29, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tazemetostat","drugSlug":"tazemetostat","fdaApproval":"2020-01-23","patentExpiry":"Sep 12, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"M-280","date":"Sep 13, 2025"},{"code":"PED","date":"Mar 13, 2026"}],"genericName":"eribulin","indications":{"approved":[{"name":"Liposarcoma","source":"DrugCentral","snomedId":254829001,"regulator":"FDA","eligibility":{"age":null,"stage":null,"biomarkers":null,"prior treatment":{"anthracycline-containing regimen":"yes"}}},{"name":"Metastatic Breast Carcinoma","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":{"age":null,"stage":null,"biomarkers":null,"prior treatment":{"taxane":"yes","anthracycline":"yes","chemotherapeutic regimens":"at least two"}}}],"offLabel":[],"pipeline":[]},"currentOwner":"Eisai Inc","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"asparaginase","brandName":"asparaginase","genericName":"asparaginase","approvalYear":"1994","relationship":"same-class"},{"drugId":"altretamine","brandName":"altretamine","genericName":"altretamine","approvalYear":"1990","relationship":"same-class"},{"drugId":"hydroxycarbamide","brandName":"hydroxycarbamide","genericName":"hydroxycarbamide","approvalYear":"1967","relationship":"same-class"},{"drugId":"pentostatin","brandName":"pentostatin","genericName":"pentostatin","approvalYear":"1991","relationship":"same-class"},{"drugId":"masoprocol","brandName":"masoprocol","genericName":"masoprocol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mitotane","brandName":"mitotane","genericName":"mitotane","approvalYear":"1970","relationship":"same-class"},{"drugId":"pegaspargase","brandName":"pegaspargase","genericName":"pegaspargase","approvalYear":"1994","relationship":"same-class"},{"drugId":"arsenic-trioxide","brandName":"arsenic trioxide","genericName":"arsenic trioxide","approvalYear":"2000","relationship":"same-class"},{"drugId":"denileukin-diftitox","brandName":"denileukin diftitox","genericName":"denileukin diftitox","approvalYear":"1999","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":["Metastatic Bladder Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Refractory Bladder Urothelial Carcinoma","Refractory Urothelial Carcinoma","Stage IV Bladder Cancer AJCC v8"],"enrollment":184,"completionDate":"2030-08-15"},{"nctId":"NCT04345913","phase":"PHASE1,PHASE2","title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-01","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Triple-Negative Breast Carcinoma","Unresectable Triple-Negative Breast Carcinoma"],"enrollment":24,"completionDate":"2026-05-07"},{"nctId":"NCT07494448","phase":"PHASE1,PHASE2","title":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07-01","conditions":["HER 2 Positive Advanced Breast Cancer","Breast Cancer"],"enrollment":24,"completionDate":"2028-05-31"},{"nctId":"NCT03237780","phase":"PHASE2","title":"Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-20","conditions":["Locally Advanced Bladder Urothelial Carcinoma","Locally Advanced Renal Pelvis Urothelial Carcinoma","Locally Advanced Ureter Urothelial Carcinoma","Locally Advanced Urethral Urothelial Carcinoma","Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis Urothelial Carcinoma","Metastatic Ureter Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Recurrent Bladder Urothelial Carcinoma","Recurrent Renal Pelvis Urothelial Carcinoma","Recurrent Ureter Urothelial Carcinoma","Recurrent Urethral Urothelial Carcinoma","Stage III Bladder Cancer AJCC v8","Stage III Renal Pelvis Cancer AJCC v8","Stage III Ureter Cancer AJCC v8","Stage III Urethral Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8","Stage IV Renal Pelvis Cancer AJCC v8","Stage IV Ureter Cancer AJCC v8","Stage IV Urethral Cancer AJCC v8","Unresectable Bladder Urothelial Carcinoma","Unresectable Renal Pelvis Urothelial Carcinoma","Unresectable Ureter Urothelial Carcinoma","Unresectable Urethral Urothelial Carcinoma"],"enrollment":72,"completionDate":"2027-06-30"},{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":["Triple-Negative Breast Cancer"],"enrollment":134,"completionDate":"2026-11-01"},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":["Breast Neoplasms"],"enrollment":558,"completionDate":"2030-09"},{"nctId":"NCT07480694","phase":"","title":"Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03","conditions":["Treatment Efficacy"],"enrollment":400,"completionDate":"2028-02"},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":["HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis"],"enrollment":184,"completionDate":"2030-12-30"},{"nctId":"NCT03424005","phase":"PHASE1,PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":["Metastatic Breast Cancer"],"enrollment":792,"completionDate":"2030-09-30"},{"nctId":"NCT06875128","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2026-01-29","conditions":["Metastatic Breast Cancer in the Liver"],"enrollment":90,"completionDate":"2029-08"},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Triple-Negative Breast Carcinoma"],"enrollment":20,"completionDate":"2028-06-30"},{"nctId":"NCT05810870","phase":"PHASE2","title":"PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2023-05-24","conditions":["Breast Cancer","Advanced Breast Cancer","Metastatic Breast Cancer"],"enrollment":14,"completionDate":"2027-07"},{"nctId":"NCT07461454","phase":"PHASE3","title":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-03-10","conditions":["Locally Advanced or Metastatic Breast Cancer"],"enrollment":376,"completionDate":"2028-06-30"},{"nctId":"NCT03207672","phase":"PHASE1","title":"Study of E7389 Liposomal Formulation in Participants With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2017-08-18","conditions":["Solid Tumor"],"enrollment":140,"completionDate":"2027-03-31"},{"nctId":"NCT07441512","phase":"PHASE2","title":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation","status":"NOT_YET_RECRUITING","sponsor":"Hu Hai","startDate":"2026-03-15","conditions":["TNBC - Triple-Negative Breast Cancer","TNBC"],"enrollment":26,"completionDate":"2028-03-15"},{"nctId":"NCT06099769","phase":"PHASE2","title":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-18","conditions":["Metastatic Breast Cancer"],"enrollment":201,"completionDate":"2027-10"},{"nctId":"NCT06449222","phase":"PHASE2","title":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-26","conditions":["Locally Advanced Breast Cancer","Triple Negative Breast Cancer","Metastatic Triple Negative Breast Cancers"],"enrollment":83,"completionDate":"2029-06"},{"nctId":"NCT02000622","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-03-27","conditions":["Breast Cancer Metastatic","BRCA 1 Gene Mutation","BRCA 2 Gene Mutation"],"enrollment":302,"completionDate":"2025-12-23"},{"nctId":"NCT05945732","phase":"","title":"DESTINY Breast Respond HER2-low Europe","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-10-24","conditions":["Unresectable Breast Cancer","Metastatic Breast Cancer","HER2-low Expressing Breast Cancer"],"enrollment":1155,"completionDate":"2028-09-01"},{"nctId":"NCT07406542","phase":"PHASE3","title":"A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-04-01","conditions":["Recurrent or Metastatic Breast Cancer"],"enrollment":400,"completionDate":"2030-04-01"},{"nctId":"NCT04078295","phase":"PHASE1,PHASE2","title":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2019-09-05","conditions":["Solid Neoplasms"],"enrollment":125,"completionDate":"2027-03-31"},{"nctId":"NCT06435429","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2024-08-13","conditions":["Metastatic HER2-positive Breast Cancer"],"enrollment":550,"completionDate":"2030-10-18"},{"nctId":"NCT04639986","phase":"PHASE3","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2020-11-23","conditions":["Metastatic Breast Cancer"],"enrollment":331,"completionDate":"2026-12"},{"nctId":"NCT05104866","phase":"PHASE3","title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":["Breast Cancer"],"enrollment":732,"completionDate":"2026-07-31"},{"nctId":"NCT07007559","phase":"PHASE1,PHASE2","title":"ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies","status":"RECRUITING","sponsor":"ALX Oncology Inc.","startDate":"2025-04-28","conditions":["Breast Cancer, Metastatic"],"enrollment":80,"completionDate":"2027-12"},{"nctId":"NCT07047365","phase":"PHASE3","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-25","conditions":["HER2-positive Advanced Breast Cancer"],"enrollment":416,"completionDate":"2028-12"},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":["Metastatic Breast Cancer","HRD-Positive/HER2-Negative Advanced Breast Cancer"],"enrollment":200,"completionDate":"2031-03"},{"nctId":"NCT06279364","phase":"PHASE3","title":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2024-02-28","conditions":["Triple Negative Breast Cancer"],"enrollment":524,"completionDate":"2026-07"},{"nctId":"NCT05374512","phase":"PHASE3","title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-05-16","conditions":["Breast Cancer"],"enrollment":644,"completionDate":"2028-11-03"},{"nctId":"NCT06519370","phase":"PHASE3","title":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-08-09","conditions":["Triple Negative Breast Cancer"],"enrollment":350,"completionDate":"2027-06-20"},{"nctId":"NCT06957886","phase":"PHASE3","title":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-05-15","conditions":["HER2-low Breast Cancer"],"enrollment":566,"completionDate":"2027-12"},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":["Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","Metastatic Breast Cancer"],"enrollment":24,"completionDate":"2029-07-31"},{"nctId":"NCT05458674","phase":"PHASE2","title":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","status":"RECRUITING","sponsor":"Criterium, Inc.","startDate":"2024-01-30","conditions":["Breast Cancer","Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer"],"enrollment":30,"completionDate":"2027-08-01"},{"nctId":"NCT07333937","phase":"PHASE2","title":"Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-12-20","conditions":["Brest Cancer"],"enrollment":35,"completionDate":"2028-11-20"},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":["Breast Cancer","Metastatic Breast Cancer","Breast Neoplasm","Breast Cancer Metastatic","End Stage Cancer"],"enrollment":404,"completionDate":"2028-06"},{"nctId":"NCT04711824","phase":"PHASE1,PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":["Breast Cancer","Brain Metastases, Adult"],"enrollment":41,"completionDate":"2026-11"},{"nctId":"NCT03331250","phase":"PHASE2","title":"Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-01-18","conditions":["Angiosarcoma","Epithelioid Hemangioendothelioma"],"enrollment":13,"completionDate":"2026-02-01"},{"nctId":"NCT03202316","phase":"PHASE2","title":"Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-11","conditions":["Recurrent Breast Inflammatory Carcinoma","Stage IV Breast Inflammatory Carcinoma"],"enrollment":37,"completionDate":"2027-12-31"},{"nctId":"NCT07088263","phase":"PHASE3","title":"Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-15","conditions":["Breast Neoplasms"],"enrollment":192,"completionDate":"2028-06-24"},{"nctId":"NCT05347134","phase":"PHASE3","title":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2022-06-10","conditions":["Triple Negative Breast Cancer"],"enrollment":254,"completionDate":"2027-06-30"},{"nctId":"NCT06081959","phase":"PHASE3","title":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2023-10-31","conditions":["Metastatic Breast Cancer"],"enrollment":376,"completionDate":"2027-12-31"},{"nctId":"NCT03526679","phase":"PHASE1,PHASE2","title":"Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-07-12","conditions":["Leiomyosarcoma","Liposarcoma","Soft Tissue Sarcoma Adult","Advanced Cancer"],"enrollment":30,"completionDate":"2025-10-30"},{"nctId":"NCT07255612","phase":"PHASE2","title":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-11-04","conditions":["Breast Cancer"],"enrollment":29,"completionDate":"2026-12-01"},{"nctId":"NCT02623972","phase":"PHASE2","title":"A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-02-26","conditions":["Inflammatory Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast"],"enrollment":22,"completionDate":"2026-12"},{"nctId":"NCT06889610","phase":"PHASE2","title":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-11-04","conditions":["Triple Negative Breast Cancer Metastatic","Melanoma Metastatic","Colorectal Cancer Metastatic"],"enrollment":95,"completionDate":"2028-12-30"},{"nctId":"NCT05530057","phase":"PHASE2","title":"Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-02-18","conditions":["Advanced Breast Cancer"],"enrollment":180,"completionDate":"2028-06-30"},{"nctId":"NCT06328738","phase":"PHASE1","title":"ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2024-05-30","conditions":["HER2-positive Breast Cancer","HER2-positive Gastric Cancer","HER2 Positive Solid Tumors","HER2 Amplification","Colorectal Cancer"],"enrollment":275,"completionDate":"2028-07"},{"nctId":"NCT04986579","phase":"PHASE2","title":"Scalp Cooling in MBC","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-10-07","conditions":["Metastatic Breast Cancer","Chemotherapy-induced Alopecia"],"enrollment":120,"completionDate":"2028-06-01"},{"nctId":"NCT06382142","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-06-21","conditions":["Triple-Negative Breast Cancer"],"enrollment":418,"completionDate":"2026-06"},{"nctId":"NCT06006273","phase":"PHASE1","title":"A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-16","conditions":["Refractory Solid Tumors"],"enrollment":48,"completionDate":"2028-12-31"},{"nctId":"NCT01676818","phase":"PHASE2","title":"Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2012-08-09","conditions":["Recurrent Cervical Cancer","Stage IIIA Cervical Cancer","Stage IIIB Cervical Cancer","Stage IVA Cervical Cancer","Stage IVB Cervical Cancer"],"enrollment":32,"completionDate":"2021-12-22"},{"nctId":"NCT05570253","phase":"PHASE2","title":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-10-03","conditions":["Breast Cancer","Metastatic Triple-Negative Breast Cancer"],"enrollment":55,"completionDate":"2027-10"},{"nctId":"NCT06957431","phase":"PHASE1","title":"Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-10-22","conditions":["Advanced Leiomyosarcoma","Adipocytic Sarcoma","Advanced Liposarcoma"],"enrollment":18,"completionDate":"2033-10-31"},{"nctId":"NCT03734029","phase":"PHASE3","title":"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-12-27","conditions":["Breast Cancer"],"enrollment":557,"completionDate":"2026-08-01"},{"nctId":"NCT07205185","phase":"PHASE2","title":"A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-01","conditions":["Soft Tissue Sarcoma (STS)"],"enrollment":46,"completionDate":"2027-12-31"},{"nctId":"NCT03264547","phase":"PHASE3","title":"A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2017-08-28","conditions":["Breast Cancer"],"enrollment":446,"completionDate":"2024-12-31"},{"nctId":"NCT06732323","phase":"PHASE3","title":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-04","conditions":["Triple-Negative Breast Cancer (TNBC)"],"enrollment":504,"completionDate":"2028-07"},{"nctId":"NCT06942234","phase":"PHASE1,PHASE2","title":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-06-01","conditions":["Inoperable Locally Advanced HER2-Negative Breast Cancer","Metastatic HER2-Negative Breast Cancer"],"enrollment":180,"completionDate":"2027-12-31"},{"nctId":"NCT03361436","phase":"PHASE1","title":"Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2018-03-19","conditions":["Liposarcoma","Malignant Abdominal Neoplasm","Malignant Retroperitoneal Neoplasm","Malignant Scrotal Neoplasm","Malignant Solid Neoplasm","Malignant Spermatic Cord Neoplasm"],"enrollment":15,"completionDate":"2033-04-14"},{"nctId":"NCT06079983","phase":"PHASE3","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-12-01","conditions":["Breast Cancer"],"enrollment":400,"completionDate":"2029-03-01"},{"nctId":"NCT02514681","phase":"PHASE3","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2015-08-01","conditions":["HER2-positive Locally Advanced or Metastatic Breast Cancer"],"enrollment":226,"completionDate":"2022-08-10"},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":["Advanced Breast Cancer"],"enrollment":27,"completionDate":"2026-06"},{"nctId":"NCT03899805","phase":"PHASE2","title":"A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-06-04","conditions":["Sarcoma","Liposarcoma","Leiomyosarcoma","Undifferentiated Pleomorphic Sarcoma"],"enrollment":57,"completionDate":"2024-07-16"},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":["Fludzoparib&#34; and Anti-angiogenic","HRD-positive/HER2-negative Advanced Breast Cancer"],"enrollment":200,"completionDate":"2031-03"},{"nctId":"NCT06263231","phase":"PHASE3","title":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intensity Therapeutics, Inc.","startDate":"2024-06-28","conditions":["Sarcoma,Soft Tissue"],"enrollment":333,"completionDate":"2028-12"},{"nctId":"NCT05217693","phase":"PHASE1","title":"A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Bliss Biopharmaceutical (Hangzhou) Co., Ltd","startDate":"2022-06-01","conditions":["Solid Tumor"],"enrollment":288,"completionDate":"2025-12-31"},{"nctId":"NCT06355024","phase":"PHASE2","title":"Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2024-05-11","conditions":["Triple-negative Breast Cancer"],"enrollment":10,"completionDate":"2025-01-01"},{"nctId":"NCT00365157","phase":"PHASE1,PHASE2","title":"Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-10-23","conditions":["Advanced Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Recurrent Urothelial Carcinoma","Stage III Bladder Urothelial Carcinoma AJCC v6 and v7","Stage IV Bladder Urothelial Carcinoma AJCC v7","Unresectable Urothelial Carcinoma"],"enrollment":132,"completionDate":"2026-07-09"},{"nctId":"NCT06590558","phase":"PHASE1","title":"Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-04","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Invasive Breast Carcinoma","Locally Advanced HER2-Negative Breast Carcinoma","Locally Advanced Hormone Receptor-Positive Breast Carcinoma","Locally Advanced Triple-Negative Breast Carcinoma","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma","Metastatic Triple-Negative Breast Carcinoma","Unresectable HER2-Negative Breast Carcinoma","Unresectable Hormone Receptor-Positive Breast Carcinoma","Unresectable Triple-Negative Breast Carcinoma"],"enrollment":0,"completionDate":"2027-05-17"},{"nctId":"NCT06343948","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-04-24","conditions":["HR+HER2- Breast Cancer"],"enrollment":383,"completionDate":"2026-05"},{"nctId":"NCT06383767","phase":"PHASE3","title":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-07-11","conditions":["Metastatic Breast Cancer"],"enrollment":378,"completionDate":"2028-07-31"},{"nctId":"NCT05041101","phase":"PHASE1,PHASE2","title":"Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-12-21","conditions":["Breast Inflammatory Carcinoma","Recurrent Breast Inflammatory Carcinoma","Stage IV Breast Inflammatory Carcinoma"],"enrollment":6,"completionDate":"2024-09-06"},{"nctId":"NCT06533722","phase":"PHASE2","title":"Adaptive Therapy for Post-Second-Line Advanced Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2024-08-04","conditions":["HER2-negative Metastatic Breast Cancer"],"enrollment":10,"completionDate":"2025-05-28"},{"nctId":"NCT02061085","phase":"PHASE2","title":"Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment","status":"COMPLETED","sponsor":"MedSIR","startDate":"2013-07","conditions":["Breast Neoplasm","Metastasis"],"enrollment":53,"completionDate":"2015-12"},{"nctId":"NCT06678048","phase":"PHASE2","title":"Arsenous Acid for Refractory Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-23","conditions":["Breast Cancer"],"enrollment":12,"completionDate":"2026-10-23"},{"nctId":"NCT03222856","phase":"PHASE2","title":"Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes","status":"COMPLETED","sponsor":"MedSIR","startDate":"2017-12-14","conditions":["Breast Cancer"],"enrollment":44,"completionDate":"2020-12-23"},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":["Advanced Malignant Solid Neoplasm","Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Fallopian Tube Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Renal Cell Carcinoma","Ovarian Carcinoma","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Primary Peritoneal Carcinoma","Stage III Lung Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8","Triple-Negative Breast Carcinoma","Unresectable Lung Non-Small Cell Carcinoma","Unresectable Melanoma","Unresectable Renal Cell Carcinoma"],"enrollment":221,"completionDate":"2024-09-16"},{"nctId":"NCT06889688","phase":"PHASE3","title":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04-01","conditions":["Breast Cancer Stage IV"],"enrollment":246,"completionDate":"2031-03-31"},{"nctId":"NCT04013217","phase":"PHASE1","title":"Evaluate Eribulin ORA in Subjects With Solid Tumors","status":"TERMINATED","sponsor":"Health Hope Pharma","startDate":"2019-07-29","conditions":["Solid Tumor"],"enrollment":10,"completionDate":"2022-03-02"},{"nctId":"NCT06775236","phase":"PHASE1,PHASE2","title":"Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-03-20","conditions":["Advanced Solid Tumors","Breast Cancer"],"enrollment":410,"completionDate":"2028-01-15"},{"nctId":"NCT02492711","phase":"PHASE3","title":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2015-08-24","conditions":["HER-2 Positive Breast Cancer","Metastatic Neoplasm"],"enrollment":624,"completionDate":"2022-06-14"},{"nctId":"NCT06857305","phase":"PHASE3","title":"Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Ma Fei，MD","startDate":"2023-07-13","conditions":["Breast Cancer Metastatic"],"enrollment":192,"completionDate":"2026-07-13"},{"nctId":"NCT05619913","phase":"PHASE2","title":"EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma","status":"RECRUITING","sponsor":"Australia New Zealand Gynaecological Oncology Group","startDate":"2023-05-22","conditions":["Ovarian Carcinosarcoma","Uterine Carcinosarcoma"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":["Metastatic Breast Cancer"],"enrollment":1460,"completionDate":"2025-12"},{"nctId":"NCT06734533","phase":"","title":"Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-12-05","conditions":["HR+ Breast Cancer"],"enrollment":80,"completionDate":"2025-12-30"},{"nctId":"NCT06731153","phase":"PHASE2","title":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-12","conditions":["Triple Negative Breast Cancer (TNBC)","Metastatic Breast Cancer"],"enrollment":40,"completionDate":"2027-12"},{"nctId":"NCT06143553","phase":"PHASE3","title":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2023-09-25","conditions":["Metastatic Breast Cancer (MBC)"],"enrollment":168,"completionDate":"2025-12"},{"nctId":"NCT06102824","phase":"PHASE2","title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-10-01","conditions":["HER2-negative Breast Cancer","Advanced Breast Cancer"],"enrollment":252,"completionDate":"2028-06-30"},{"nctId":"NCT05824975","phase":"PHASE1,PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Soft Tissue Sarcoma (STS)","Platinum-resistant Ovarian Cancer (PROC)","Hepatocellular Carcinoma (HCC)","Colorectal Cancer (CRC)","HER2 Negative Breast Cancer","Cutaneous Melanoma","Renal Cell Carcinoma (RCC)"],"enrollment":358,"completionDate":"2027-04-24"},{"nctId":"NCT06678230","phase":"PHASE2","title":"Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2024-11","conditions":["Breast Cancer"],"enrollment":40,"completionDate":"2025-10-20"},{"nctId":"NCT01827787","phase":"PHASE2","title":"Eribulin in HER2 Negative Metastatic BrCa","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-05","conditions":["Breast Cancer"],"enrollment":83,"completionDate":"2016-05"},{"nctId":"NCT03901339","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-08","conditions":["Metastatic Breast Cancer"],"enrollment":543,"completionDate":"2023-10-20"},{"nctId":"NCT03840772","phase":"PHASE2","title":"Eribulin in Advanced Solitary Fibrous Tumor","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2019-07-17","conditions":["Solitary Fibrous Tumor"],"enrollment":16,"completionDate":"2024-09-18"},{"nctId":"NCT02681523","phase":"PHASE2","title":"ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2015-10-28","conditions":["Breast Cancer"],"enrollment":8,"completionDate":"2018-07-24"},{"nctId":"NCT02037529","phase":"PHASE3","title":"Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer","status":"SUSPENDED","sponsor":"Academic and Community Cancer Research United","startDate":"2014-01-17","conditions":["Breast Adenocarcinoma","HER2/Neu Negative","Invasive Breast Carcinoma","Stage IIIC Breast Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":201,"completionDate":"2024-10-31"},{"nctId":"NCT06539559","phase":"PHASE2","title":"Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Wang Jiayu","startDate":"2024-08-01","conditions":["Breast Neoplasms","Neoplasm Metastasis","Drug Therapy","Bevacizumab"],"enrollment":60,"completionDate":"2026-08-01"},{"nctId":"NCT06387628","phase":"PHASE2","title":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-10","conditions":["TNBC - Triple-Negative Breast Cancer"],"enrollment":74,"completionDate":"2027-04-01"},{"nctId":"NCT04464174","phase":"PHASE2","title":"Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-08","conditions":["Triple Negative Breast Cancer"],"enrollment":54,"completionDate":"2023-11-10"},{"nctId":"NCT06355037","phase":"PHASE2","title":"Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-05-20","conditions":["Triple-negative Breast Cancer"],"enrollment":10,"completionDate":"2025-01-31"},{"nctId":"NCT03393741","phase":"","title":"Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-29","conditions":["Breast Cancer","Breast Neoplasms"],"enrollment":5,"completionDate":"2024-02-11"}],"_emaApprovals":[{"date":"2011-03-17","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Halaven"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000182254","MMSL":"178296","NDDF":"013558","UNII":"LR24G6354G","VUID":"4030296","CHEBI":"CHEBI:70710","VANDF":"4030296","INN_ID":"8854","RXNORM":"1045452","UMLSCUI":"C2350866","chemblId":"CHEMBL1683590","ChEMBL_ID":"CHEMBL1683590","KEGG_DRUG":"D08914","DRUGBANK_ID":"DB08871","PDB_CHEM_ID":"6K9","PUBCHEM_CID":"11354606","SNOMEDCT_US":"448800004","IUPHAR_LIGAND_ID":"6813","SECONDARY_CAS_RN":"441045-17-6","MESH_SUPPLEMENTAL_RECORD_UI":"C490954"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2010-","companyName":"Eisai Inc","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"37.8 hours","clearance":"0.75 mL/min/kg","fractionUnbound":"0.43%","volumeOfDistribution":"1.46 L/kg"},"publicationCount":1130,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:58:18.765841+00","atcClassification":{"source":"DrugCentral","atcCode":"L01XX41","allCodes":["L01XX41"]},"biosimilarFilings":[],"originalDeveloper":"Eisai Inc","recentPublications":[{"date":"2026 Mar 27","pmid":"41894563","title":"CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"date":"2026 Feb 23","pmid":"41892363","title":"Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay.","journal":"Epigenomes"},{"date":"2026 Mar 23","pmid":"41879493","title":"Marine-Derived Anticancer Compounds and their Clinical Status.","journal":"Anti-cancer agents in medicinal chemistry"},{"date":"2026 Mar 19","pmid":"41855129","title":"Across borders and histologies: Rethinking endpoints for vascular sarcoma trials.","journal":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"date":"2026 Mar 19","pmid":"41854792","title":"Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.","journal":"Breast cancer research and treatment"}],"companionDiagnostics":[],"genericManufacturers":8,"_genericFilersChecked":true,"genericManufacturerList":["Baxter Hlthcare Corp","Chia Tai Tianqing","Dr Reddys","Gland","Glenmark Pharms Inc","Jiangxi Kvvit Pharm","Long Grove Pharms","Sandoz"],"status":"approved","companyName":"Eisai Inc","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"2010","aiSummary":"","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-11-15T00:00:00.000Z","mah":"EISAI INC","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":26,"withResults":6},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:06:03.887266+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}